The Science and Translation of Lactate Shuttle Theory. by Brooks, George A
UC Berkeley
UC Berkeley Previously Published Works
Title
The Science and Translation of Lactate Shuttle Theory.
Permalink
https://escholarship.org/uc/item/3307p0k9
Journal
Cell metabolism, 27(4)
ISSN
1550-4131
Author
Brooks, George A
Publication Date
2018-04-01
DOI
10.1016/j.cmet.2018.03.008
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Cell Metabolism
Review
The Science and Translation
of Lactate Shuttle Theory
George A. Brooks1,*
1Exercise Physiology Laboratory, Department of Integrative Biology, University of California, Berkeley, Berkeley, CA 94720, USA
*Correspondence: gbrooks@berkeley.edu
https://doi.org/10.1016/j.cmet.2018.03.008
Once thought to be a waste product of anaerobic metabolism, lactate is now known to form continuously
under aerobic conditions. Shuttling between producer and consumer cells fulfills at least three purposes
for lactate: (1) a major energy source, (2) the major gluconeogenic precursor, and (3) a signaling molecule.
‘‘Lactate shuttle’’ (LS) concepts describe the roles of lactate in delivery of oxidative and gluconeogenic sub-
strates as well as in cell signaling. In medicine, it has long been recognized that the elevation of blood lactate
correlates with illness or injury severity. However, with lactate shuttle theory in mind, some clinicians are now
appreciating lactatemia as a ‘‘strain’’ and not a ‘‘stress’’ biomarker. In fact, clinical studies are utilizing lactate
to treat pro-inflammatory conditions and to deliver optimal fuel for working muscles in sports medicine. The
above, as well as historic and recent studies of lactate metabolism and shuttling, are discussed in the
following review.
Introduction
Once thought to be the consequence of oxygen deficits in
contracting skeletal muscle, we now know that the L-enantiomer
of the lactate anion is formed and utilized continuously in diverse
cells under fully aerobic conditions. In fact, as the product of
one metabolic pathway (glycolysis) and the substrate for a
downstream pathway (mitochondrial respiration), lactate can
be regarded as the link between glycolytic and aerobic pathways
(Figure 1). Importantly, according to the lactate shuttle hypothe-
sis, this linkage occurs under fully aerobic conditions and can
transcend compartment barriers and occur within and among
cells, tissues, and organs (Brooks, 1984, 2002, 2009). In contrast
to its early portrayal as a metabolic waste product and fatigue
agent, lactate is the chief messenger in a complex feedback
loop. Short-term challenges to adenosine triphosphate (ATP)
supply stimulate lactate production, leading to immediate, short-
and long-term cellular adaptions to support ATP homeostasis.
The physiology and biochemistry of this topic were extensively
reviewed by Bruce Gladden in 2004 and should be consulted
(Gladden, 2004), but subsequently new information has become
available, particularly with regard to the role of lactate and lactate
shuttle, to understand basic physiology and metabolism as well
as to treat injuries and illnesses.
At the whole-body level, lactate metabolism is understood to
be important for at least three reasons: (1) lactate is a major
energy source (Bergman et al., 1999b; Brooks et al., 1991a;
Mazzeo et al., 1986; Stanley et al., 1985, 1986); (2) lactate is
the major gluconeogenic precursor (Bergman et al., 2000;
Emhoff et al., 2013b; Meyer et al., 2002a; Stanley et al., 1988);
and (3) lactate is a signaling molecule with autocrine-, paracrine-
and endocrine-like effects and has been called a ‘‘lactormone’’
(Brooks, 2002, 2009; Hashimoto et al., 2007). ‘‘Cell-cell lactate
shuttle’’ and ‘‘intracellular lactate shuttle’’ concepts describe
the roles of lactate in delivery of oxidative and gluconeogenic
substrates as well as in cell signaling (Brooks, 2002, 2009)
(Figure 2). Examples of the cell-cell lactate shuttles include
lactate exchanges between white-glycolytic and red-oxidative
fiberswithin aworkingmuscle bed and betweenworking skeletal
muscle and heart (Bergman et al., 2009; Gertz et al., 1981, 1988),
brain (Glenn et al., 2015b; Quistorff et al., 2008; van Hall et al.,
2009), liver and kidneys (Bergman et al., 2000; Emhoff et al.,
2013b; Meyer et al., 2002b; Woerle et al., 2003), astrocytes
and neurons (Pellerin et al., 1998), and vice versa (i.e., neurons
and astrocytes) (Liu et al., 2017) (Figure 1B). Examples of intra-
cellular lactate shuttles include cytosol-mitochondrial (Brooks
et al., 1999a; Butz et al., 2004) and cytosol-peroxisome
exchanges (McClelland et al., 2003). Indeed, most if not all
cell-cell and intracellular lactate shuttles are driven by a concen-
tration or pH gradient or by redox state.
Subsequent to and coincident with findings of high rates of
lactate flux, oxidation, and gluconeogenesis in healthy rodents
(Brooks and Donovan, 1983; Donovan and Brooks, 1983) and
humans during rest and submaximal exercise (Mazzeo et al.,
1986; Stanley et al., 1988) were observations that lactate
traverses membrane barriers by facilitated, carrier-mediated
lactate anion and proton exchange (Dubouchaud et al., 2000;
Garcia et al., 1994; Roth and Brooks, 1990a, 1990b) involving a
family of lactate/pyruvate monocarboxylate transport (MCT)
proteins (Garcia et al., 1994, 1995; Price et al., 1998). MCT
protein isoform expression patterns vary with muscle fiber type
(Hashimoto et al., 2005, 2006), and MCTs are expressed in
tissues and cellular organelles that rapidly exchange lactate,
including the brain (Hashimoto et al., 2008; McClelland et al.,
2003; Pellerin et al., 2005). Importantly, MCTs are bidirectional
(Brown and Brooks, 1994), allowing for tissues to switch
between lactate release and uptake depending on changes in
concentration and pH. For example, lactate release from a
muscle occurs when contractions start and rate of lactate
appearance (Ra) increases; this is followed by lactate uptake
as muscle oxygen consumption reaches a new steady state
and the rate of lactate disappearance (disposal, Rd) exceeds
production and hence Ra of lactate (Bergman et al., 2009;
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Stanley et al., 1986). Further, changes in MCT expression can
occur rapidly, as happens following neurotrauma in rats (Prins
and Giza, 2006).
The roles of lactate as a metabolic substrate and critical
signaling molecule continue to gain support with ongoing
research (Elustondo et al., 2013; Jacobs et al., 2013). In intact
functioning humans (Miller et al., 2002a, 2002b), in working
human skeletal muscles (Bergman et al., 1999b; Stanley et al.,
1986), as well as in the hearts of those individuals (Bergman
et al., 2009; Gertz et al., 1981, 1988), lactate is preferred over
glucose as a fuel. Similarly, lactate is preferred over glucose as
a fuel in brain preparations (Schurr, 2006, 2008; Schurr and
Payne, 2007) and in vivo (Hashimoto et al., 2018; van Hall et al.,
2009). The astrocyte-neuron lactate shuttle (ANLS) posits that
lactate is extruded by astrocytes and then actively consumed
and oxidized by neurons involved in glutamatergic signaling
(Pellerin et al., 1998). Relevant to lactate shuttling in brain (Barros,
2013; Be´langer et al., 2011), neurons possess the cellular compo-
nents necessary for glucose uptake and use by an intracellular
lactate shuttle (Hashimoto et al., 2008), and a post-trauma neuro-
protective role of lactate has been proposed (Holloway et al.,
2007; Schurr and Gozal, 2012). From the earliest work on plasma
membrane lactate exchange, it was recognized that lactate trans-
porters are symporters moving solute down anion and proton
concentration gradients (Roth and Brooks, 1990a, 1990b), which
is consistent with more recent studies, for example between
astrocytes and neurons (M€achler et al., 2016). Hence, it is not
surprising that Bellen and colleagues (Liu et al., 2017) have
described a neuron-glia lactate shuttle linked to lipid transfer
that may be disrupted in Alzheimer’s disease (Bailey et al., 2015).
At both systemic and cerebral levels, it is clear that glucose-
lactate interactions are essential in normal physiology as well
as pathophysiology. Conditions in which lactate metabolism is
important in normal physiological function include: energy sup-
ply (Brooks, 1986; Mazzeo et al., 1986; Stanley et al., 1985),
maintenance of glycemia (Bergman et al., 2000; Emhoff et al.,
2013b; Stanley et al., 1988), maintenance of cerebral meta-
bolism in the face of hypoglycemia (Herzog et al., 2013), cerebral
metabolism and signaling (Liu et al., 2017; Pellerin and Magis-
tretti, 1994), and cerebral executive function (Hashimoto et al.,
2018). Clinical conditions in which lactate therapy may be effica-
cious include glucose control (Bouzat et al., 2014;Wolahan et al.,
2017), traumatic brain injury (Brooks and Martin, 2015), heart
failure (Nalos et al., 2014), dengue (Somasetia et al., 2014),
endotoxic shock (Duburcq et al., 2014; Junarsa et al., 2015),
inflammation (de-Madaria et al., 2017), immunosuppressive
role in sepsis (Nolt et al., 2018), and fluid resuscitation (Marques
et al., 2017). Of the several goals in authoring this review,
certainly one is to lift the veil of confusion around ‘‘lactate’’: is
it a metabolic poison and fatigue agent (Hill, 1924; Hill and
Lupton, 1923; Meyerhof, 1920), or are there necessary and
positive attributes to lactate formation and disposal (Brooks,
1984; Cori and Cori, 1946)? Most likely, the latter is true.
Physiology
Glycolysis
Since 3000 BCE, beer and wine making were known in ancient
Egypt. Historically, it is also known that fermentation makes
milk and cabbage sour. Glycolysis in tissues deprived of oxygen
results in lactate and acid production and accumulation
(Fletcher, 1907; Meyerhof, 1920; Pasteur, 1863). But does
glycolysis produce lactate or lactic acid with a 1:1 proton-to-
lactate anion stoichiometry in perfused and oxygenatedmuscles
and other tissues of humans and mammalian model systems?
Most likely, a 1:1 lactate anion:proton production ratio does
not occur in mammalian systems in vivo.
Since the inception of modern physiology and biochemistry,
researchers have associated lactic acid accumulation with
Figure 1. The Lactate Shuttle Concept
(A) The lactate shuttle concept depicting lactate as the vehicle linking
glycolytic and oxidative metabolism. Linkages between lactate ‘‘producer’’
and ‘‘consumer’’ exist within and among cells, tissues, and organs. As the
product of one metabolic pathway (glycolysis) and the substrate for a
downstream pathway of disposal (mitochondrial respiration), lactate is the link
between glycolytic and aerobic pathways. Importantly, according to the
lactate shuttle hypothesis, this linkage occurs continuously under fully aerobic
conditions, can transcend compartment barriers, and can occur within and
among cells, tissues, and organs. Modified from Brooks, 1984.
(B) Depiction of the cell-cell lactate shuttle within a tissue bed. Lactate
exchanges between blood and producer and consumer cells moving down
lactate and proton concentration gradients. Although both cell types are
glycolytic, lactate concentration is greatest in highly glycolytic producer cells
and lowest in highly oxidative consumer cells in which lactate is an oxidizable
substrate in the mitochondrial reticulum. Depending on the physiological
circumstance, such as continuous physical exercise, blood lactate concen-
trationwill be intermediate: that is, higher than in consumer cells but lower than
in producer cells. Hence, lactate flux from blood to oxidative consumer cells
within working muscle sometimes achieves net muscle uptake even while
lactate is produced in highly glycolytic cells (Bergman et al., 1999b). Cell-cell
lactate shuttling is typical of continuous exercise and diverse other situations
such as astrocyte-neuron lactate shuttle (Pellerin and Magistretti, 2012).
Modified from Brooks, 1984.
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muscle fatigue (Fletcher, 1907; Hill, 1914; Hill and Lupton,
1923). A then-contemporaneous interpretation of results on
electrically stimulated but unperfused and non-oxygenated
frog muscle and frog hemi-corpus preparations was that lactic
acid accumulation caused muscle fatigue (vide infra). Exploring
the cause of fatigue was not an experimental purpose of Otto
Meyerhof (Meyerhof, 1920); rather, his purpose was to quanti-
tate glycogen-lactate relationships and establish that glycogen
was the precursor to lactate. Hence, from its inception there
has been confusion about lactic acid production and muscle
fatigue.
Additional confusion in discriminating between effects of
lactate and lactic acid relates to common occurrences in phys-
iology and metabolism. In vivo lactatemia is typically, but not
always, accompanied by hydrogen ion accumulation (acidosis)
because metabolic stress gives rise to glycolysis, ATP hydro-
lysis, and carbonic acid formation and dissociation. Then
again, because MCTs are symporters moving lactate anions
and protons simultaneously, in effect, MCTs are lactic acid
transporters. In other situations, when sodium-lactate
solutions are given orally or intravenously for experimental or
therapeutic purposes, a mild alkalosis results (Miller et al.,
2005) Hence, in different situations it is important to consider
the individual or combined effects of lactate anions and
hydrogen ion.
Lactate and Acidosis
While it remains uncertain whether glycolysis produces lactate
or lactic acid, it is certain that acidosis occurs in exercise and
other conditions. However, the parameter we describe as pH
in physiology and pathophysiology is far more complicated
than the production of protons in any single metabolic
pathway. From the work of Peter Stewart, we realize that
blood pH ([H+]) is a dependent variable influenced by the par-
tial pressure of CO2 (PCO2), the concentration of weak acid
Figure 2. Depiction of the Lactate Shuttle as
It Fulfills Three Physiological Functions
Lactate is a major energy source; is the major
gluconeogenic precursor; is a signaling molecule
with autocrine-, paracrine- and endocrine-like
effects; and has been called a ‘‘lactormone.’’
‘‘Cell-cell’’ and ‘‘intracellular lactate shuttle’’ con-
cepts describe the roles of lactate in delivery of
oxidative and gluconeogenic substrates as well as
in cell signaling. Examples of the cell-cell lactate
shuttles include lactate exchanges between
white-glycolytic and red-oxidative fibers within a
working muscle bed and between working skel-
etal muscle and heart, brain, liver, and kidneys.
Examples of intracellular lactate shuttles include
cytosol-mitochondrial and cytosol-peroxisome
exchanges. Indeed, most if not all lactate shuttles
are driven by a concentration or pH gradient or by
redox state. G, glucose and glycogen; L, lactate.
Compiled from diverse sources (Brooks, 1984,
2002, 2009).
buffers ([Atot], in plasma mainly amino
acids and proteins), and the strong ion
difference (SID), which is calculated as
the sum of the strong cation concentra-
tions minus the sum of the strong anions
(Kowalchuk et al., 1988; Miller et al., 2005):
SID (meq/L) = ([Na+] + [K+] + [Ca++] + [Mg++]) ! ([Cl!] + [Lac!]).
Although technical difficulties and conceptual criticisms of the
Stewart SID approach have precluded its universal adoption in
clinical situations (Morgan, 2009), in theory and for research pur-
poses the Stewart approach does inform that lactate anion
(Lac!) is but one factor increasing [H+] (decreasing pH) and
that whether glycolysis produces protons or not, protons from
glycolysis do not affect blood [H+] on a one-to-one basis.
Further, the Stewart approach helps us understand why infusion
of lactate-containing solutions (e.g., Na+-lactate) raises blood
pH. Regardless of tight or loose coupling between rates of
lactate and proton production, clearly glycolysis makes lactate;
as discussed in this review, this product of glycolysis is an impor-
tant fuel and signaling molecule. So it is critical to consider the
physiological factors that stimulate lactate production. As dis-
cussed below, oxygen availability was classically considered
to be a primary driver of lactate production, although there are
numerous reasons to reconsider this simplistic view.
Lactate and Oxygen Lack (Anaerobiosis)
Discounting for now theWarburg effect in cancer (Warburg et al.,
1927; vide infra), we now have a good understanding of the
disposal of glycolytic flux products during rest and during stress-
ful conditions such as exercise, high altitude exposure, trauma,
and sepsis (Figure 3). Importantly, there is no solid experimental
support for the traditional view that glycolytic flux is directed to
mitochondrial respiration solely through pyruvate uptake by the
mitochondrial reticulum. In the past it was assumed by many
that the rising lactate abundance in the body indicated anaerobic
conditions at the cellular level, but our understanding of lactate
as a metabolically valuable carbohydrate has now replaced
this traditional view. Experimental support is lacking for the
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notion that glycolytic flux is directed to lactate production only
when oxygen is lacking. Similarly, there is no evidence that the
first step in lactate oxidation (i.e., conversion to pyruvate) occurs
in the cytosol of any tissue, including the beating heart or working
skeletal muscle, that has a lactate-to-pyruvate concentration
ratio (L/P) > 100 (Henderson et al., 2007) and that are net glucose
consumers (Bergman et al., 2009). In contrast, there is strong ev-
idence that glucose and glycogen catabolism proceed to lactate
production under fully aerobic conditions (Bendahan et al., 2017;
Richardson et al., 1998; Rogatzki et al., 2015) (Figure 3).
The first evidence for lactate production and oxidative
disposal of lactate on working muscle was generated on dog
gracilis and gastrocnemius muscle preparations (Connett et al.,
1990; Jo¨bsis and Stainsby, 1968; Stainsby and Welch, 1966)
and subsequently in working human muscles (Bendahan et al.,
2017; Richardson et al., 1998). In muscles and arterial blood of
resting healthy humans, lactate concentration approximates
1.0 mM, while pyruvate concentration approximates 0.1 mM,
the L/P ratio being 10 (Henderson et al., 2007). In this resting
state, net lactate production and release from resting muscle
of healthy individuals (Bergman et al., 1999b; Stanley et al.,
1986) occurs when intramuscular partial pressure of oxygen
(PO2) approximates 40 Torr (Richardson et al., 1998), well above
the critical mitochondrial PO2 for maximal mitochondrial respira-
tion (1–2 Torr) (Bendahan et al., 2017; Rumsey et al., 1990). Dur-
ing exercise at about 65% of maximal oxygen consumption
(VO2max), net lactate production and release fromworking mus-
cle beds rise with a corresponding increase in L/P more than an
order of magnitude (to"500), but the intramuscular PO2 remains
at 3–4 Torr, well above the critical mitochondrial O2 level (Bend-
ahan et al., 2017; Richardson et al., 1998). Hence, it is appro-
priate to conclude that in healthy humans glycolysis proceeds
to lactate under fully aerobic conditions, as it must because
the Keq of lactate dehydrogenase (LDH) approximates 1,000
(Rogatzki et al., 2015). Importantly, most lactate (75%–80%) is
disposed of immediately within the tissue or subsequent to
release and reuptake by working muscle (Bergman et al.,
1999b; Stanley et al., 1986), with significant uptake and oxidation
by heart (Bergman et al., 2009; Gertz et al., 1988), brain (Glenn
et al., 2015b; van Hall et al., 2009), and liver for gluconeogenesis
(Bergman et al., 2000; Emhoff et al., 2013b; Stanley et al., 1988).
Characterization of lactate as a dynamic fuel, produced even
when oxygen is not lacking, redefines this molecule from being
an apparent nuisance physiologically to being of metabolic
benefit. Similarly, as discussed below, views have evolved
over the years regarding the role of lactate (and/or associated
protons) in causing muscle fatigue.
Lactate and Fatigue
Working with electrically stimulated but unperfused and non-
oxygenated frog preparations, early researchers observed that
muscle contraction was associated with lactic acid accumula-
tion (Fletcher, 1907; Hill, 1914; Hill and Lupton, 1923; Meyerhof,
1920). Subsequently, in human experimentation, early investiga-
tors associated fatigue with limitations in oxygen supply (Hill and
Lupton, 1923), and fatigue from high-intensity exercise consis-
tently produces results of high [lactate] and proton accumulation
(reduced pH) (Bangsbo et al., 1993; Sahlin et al., 1976); the tradi-
tional conclusion has been that lactic acid causes muscle
fatigue. In relating lactate accumulation and fatigue, one might
wonder why early and more recent investigators of physiology
didn’t conclude that lactate production was a means to ward
off fatigue.
Because of the central role of lactate in intermediary meta-
bolism and exercise performance, investigators in muscle and
exercise physiology have made serious effort to distinguish
between the separate effects of lactate anions and hydrogen
ions on muscle performance. At present it is appropriate to
conclude that exercise causes lactate anion and proton accu-
mulation. However, it is unclear whether glycolysis makes lactic
acid or if accumulated lactate anions and protons are derived
from the same sources. It is also unclear if these compounds
(lactate and hydrogen ions), individually, separately, or in aggre-
gate, are causes of muscle fatigue in vivo. And even if lactatemia
and decreased muscle and blood pH are fatigue agents,
certainly they are not the only causes of fatigue (Fitts, 1994).
In considering the effect of lactate anion on muscle function,
Allen and Lamb (Allen et al., 2008) reviewed results of their
Figure 3. Glycolysis Produces Lactate, Not Pyruvate
There is strong evidence that glucose and glycogen catabolism proceed to
lactate production under fully aerobic conditions in studies on intact animals,
animal tissue preparations, and humans. Results of studies on human subjects
clearly show that lactate production occurs under fully aerobic conditions. In
muscles and arterial blood of resting healthy humans, lactate concentration
approximates 1.0 mM, while pyruvate concentration approximates 0.1 mM,
the lactate/pyruvate (L/P) being 10; the results show that glycolysis progresses
to lactate under fully aerobic conditions. Further, in resting muscles of healthy
individuals, the intramuscular partial pressure of oxygen (PO2) approximates
40 Torr, well above the critical mitochondrial PO2 for maximal mitochondrial
respiration (1–2 Torr). Clearly, net lactate production and release occur when
oxygen is ample (Bendahan et al., 2017; Connett et al., 1990; Rumsey et al.,
1990). During exercise at about 65% of maximal oxygen consumption
(VO2max), lactate production and net lactate release from working muscle
beds rise, and the L/P rises more than an order of magnitude (to"500), but the
intramuscular PO2 remains at 3–4 Torr, well above the critical mitochondrial
O2 level. Hence, it is appropriate to conclude that in healthy humans,
glycolysis proceeds to lactate under fully aerobic conditions. Importantly,
most (75%–80%) of lactate is disposed of immediately within the tissue or
subsequent to release and reuptake by working muscle, with significant
uptake and oxidation by heart for oxidation and liver for gluconeogenesis.
From diverse sources (Bergman et al., 1999b; Connett et al., 1990; Henderson
et al., 2007; Richardson et al., 1998; Stanley et al., 1986).
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own studies as well as the literature on the subject. Conse-
quently, they could not accept the hypothesis that lactate anion
accumulation caused muscle fatigue. Indeed, we now know that
compared to glucose or fructose (Jeukendrup et al., 2006), oral
consumption of arginyl lactate can improve exercise perfor-
mance (Azevedo et al., 2007). Similarly, we now know that
vascular sodium-lactate infusion provides an energy substrate,
spares glucose, and has a slightly alkalizing effect on blood pH
(Miller et al., 2002a, 2002b, 2005). Further, in the clinical setting
it has been noted that vascular lactate infusion can improve
cardiac performance in heart failure (Nalos et al., 2014). If the
data on a fatigue effect of lactate anion are unconvincing, what
then about the potential effect of hydrogen ion on muscle
performance?
In terms of isolated muscle models of fatigue, results of recent
reports and a review on the subject support the conclusion that
the combined effects of acidosis, phosphate ion accumulation,
and low Ca2+ (Debold et al., 2016) (as occurs in fatigue) interfere
with cross-bridge cycling and hence muscle performance. How-
ever, those results and interpretations based on isolated muscle
models are to be considered alongside those of de Paoli and
colleagues (de Paoli et al., 2007), who showed that the addition
of lactic acid and adrenaline to isolated, electrically stimulated
rat soleus muscles increased excitability and relieved fatigue.
In those experiments, a rise in extracellular K+ due to release
during excitation-coupling or added KCl caused disruption of
the cell membrane electrical gradient that was corrected by
the addition of lactic acid to the preparation. Hence, at present
it is uncertain that proton accumulation during human muscle
exercise is a major cause of muscle fatigue.
Now, with the benefit of almost a century of experimenta-
tion, we know that glycolysis is a means to produce ATP
that allows cellular work to progress. Importantly, an accepted
concept is that glycolysis is beneficial because it yields ATP
(2 mol ATP/mol glucose and 3 mol ATP/mol glucosyl subunit
of glycogen). As well, glycolysis produces lactate, an oxidiz-
able substrate that downstream gives rise to a rich supply of
ATP (Brooks, 1985). Fairly recently also, the idea has been
advanced that glycolysis is pH neutral because it produces
lactate anion, as opposed to lactic acid (Hochachka and
Mommsen, 1983; Robergs et al., 2004). For instance, consider
the terminal step in glycolysis catalyzed by LDH: pyruvate!
anion + NADH + H+/ lactate! anion + NAD+; acid is not pro-
duced, but to the contrary, is removed, with a total accounting
of the path from glucose to lactate being pH neutral and from
glycogen to lactate being slightly alkalotic (Robergs et al.,
2004). Hence, as suggested originally by Hochachka and
Mommsen and supported by the accounting of Robergs
et al., it is uncertain whether glycolysis produces lactate or
lactic acid; they would argue for the former.
The idea that glycolysis does not produce acid has been
challenged (Boning and Maassen, 2011; Gladden, 2008), largely
because Robergs et al. could not explain where protons came
from during physical exercise that stimulates glycolysis. The
explanation of Robergs and colleagues, that ATP hydrolysis
was the source of protons during exercise, is considered unten-
able because working muscle [ATP] is homeostatic. However,
the criticism of Robergs et al. is perhaps not completely justified,
because the source of protons in muscle contraction is unknown
and the effects of muscle proton production on muscle and
blood pH are not clear (Lindinger and Heigenhauser, 2008). To
reiterate from above, according to the Stewart approach, blood
pH is a dependent variable influenced by PCO2, the concentra-
tion of weak acid buffers, and the strong ion difference.
Perhaps the strongest data that glycolysis produces protons
and lactate anions on a 1:1 basis comes from Marcinek et al.
(2010), who measured proton and ATP concentration changes
in an ischemic mouse muscle model using 31P-MRS and lactate
anion accumulation biochemically. In the 31P-MRSmethod, pro-
ton formation is determined from splitting of the phosphate peak,
making the measurement critically important for determining
muscle energetics from MRS. With no observed change in
[ATP] in the muscle preparation, the data of Marcinek et al. indi-
cated that proton generation agreed closely with the increases in
lactate anions over the course of the ischemic period. Hence,
their data supported a 1:1 stoichiometry between lactate and
proton generation. However, while the experimental paradigm
could measure protons, the source of those protons was not
identified. Further, the experimental paradigm is less than ideal,
and results are inconsistent with observations of lactate anion
and proton accumulation in and release from working skeletal
muscles that do not show the 1:1 lactate anion:proton ratio
(Bangsbo et al., 1993, 1996, 1997; Juel et al., 1990).
In summary on this section, after a century of effort, what can
we conclude on the interrelationships among cell work (e.g.,
muscle contraction), glycolysis, lactate, and proton accumula-
tion? We can conclude that cell work stimulates glycolysis and
also lactate anion and proton formation, but there is persistent
controversy over whether glycolysis produces lactate or lactic
acid. Further, there is similar controversy over whether either
lactate anion or proton accumulation interferes with the mecha-
nism ofmuscle contraction and causes fatigue. Certainly, glycol-
ysis is necessary for muscle power generation, and certainly also
lactate provides a fuel energy source. As well, results of the work
of de Paoli et al. (2007) can be interpreted to mean that lactate
and lactic acid prevent extracellular K+ accumulation from inter-
fering with action of Na+ channels in working muscle. In sum, as
implied in proponents of the maximal lactate steady state
(Hofmann and Pokan, 2010), it can be concluded that rising
lactate and falling pH in working muscle give evidence of
disturbances to metabolic and acid/base homeostasis in work-
ing muscle that lead to termination of effort. To exemplify the
complexity of the relationship between physical work capacity,
lactate concentration during exercise, and fatigue, the case of
high altitude exposure is discussed below.
Lactate at Altitude, the Lactate Paradox
When confronting the physiological stresses of high altitude
exposure, early investigators noted that blood [lactate] was
elevated at rest and during submaximal exercise intensities
(Reeves et al., 1992). The natural thinking at the time was based
on O2 debt theory and the assumption that a deficit in oxygen
consumption, i.e., a ‘‘Pasteur effect,’’ was responsible for the
elevation in circulating [lactate]. The term ‘‘Pasteur effect’’ for a
stimulation in glucose use due to a limitation in O2 supply is
attributable to Warburg (Warburg, 1926), who drew a contrast
between glucose use and lactate production in normal and
cancer cells that consumed glucose and produced lactate
regardless of the availability of oxygen (Warburg et al., 1927).
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However, the assumption of a Pasteur effect in men working at
altitude is untenable, because pulmonary oxygen consumption
rate at altitude is the same as at sea level for a given power
output. As well, early investigators were perplexed to discover
that blood lactate accumulation after maximal effort was lower
at altitude than at sea level. Still, the setting of high-altitude
research has provided an outstanding opportunity to understand
physiology and metabolism. Because of inconsistencies be-
tween observed results in men exercising at altitude and results
anticipated based on assumption of a Pasteur effect, early inves-
tigators deemed the inconstancies to be paradoxes.
Now, based on isotope and limb balance studies, we know
that acute exposure to high-altitude hypoxemia results in sym-
pathetic activation that raises blood epinephrine (Mazzeo
et al., 1995) and consequently lactate turnover in resting men
and those engaged in exercises at given exercise power outputs
(Brooks et al., 1998). From the same experiments, we now know
also that the sympathetic response to altitude is blunted with
acclimation such that blood epinephrine, [lactate], and lactate
Ra are reduced compared to acute exposure, but not compared
to sea-level normoxic exposure. Therefore, one ‘‘lactate
paradox’’ at altitude is related to the effects of epinephrine in
determining lactate production and hence blood Ra.
Referred to above is the paradoxical finding of a lower rather
than higher blood lactate concentration on maximal exertion at
altitude compared to sea level. This phenomenon is attributable
to greatly reduced exercise power outputs at altitude. Reduced
muscle work requires less glycolysis that results in lower lactate
production and blood Ra.
And finally, still another lactate paradox observed in altitude
sojourners is that while hypoxia and hypoxemia persist after
acclimation, blood [lactate] is lower than on acute exposure
while lactate Ra is greater than at sea level (Brooks et al.,
1991a). The increased lactate Ra after acclimation is due to an
increased dependence on glucose relative to sea level (Brooks
et al., 1991b) and improved lactate clearance relative to acute
altitude exposure (Brooks et al., 1991a).
Energetics of Lactate Production
It is safe to state that glycolysis is the entry pathway for
catabolism of products of carbohydrate digestion (Brooks
et al., 2005). Substrate-level phosphorylation of glucose
yields a net of 2 ATP/mol of glucose, and assuming a DG of
!11 kcal/mol for ATP, glycolysis yields!22 kcal/mol of glucose.
Subsequently, continued catabolism of monocarboxylates
(pyruvate and lactate) from glucose through the mitochondrial
tricarboxylic acid cycle (TCA) and electron transport chain
(ETC) yields an additional 32–34 mol ATP/mol glucose (Brooks
et al., 2004). Overall, the oxidative catabolism of carbohydrate
moieties yields z4 kcal/g, or 34–36 mol ATP/mol glucose
(Brooks et al., 2004). As well, in terms of energetics, glycolysis
is important for non-oxidative (‘‘glycolytic’’ or ‘‘anaerobic’’)
power production (Brooks, 2012).
Among the several functions of glycolysis, perhaps most
notable is that the process engenders both sustained,
oxidative and short-term, glycolytic high muscle power output
activities. There are two modes of glycolytic function during
exercise: (1) continuous glycolysis with lactate production
(Ra) matched by oxidative disposal (Rd) and (2) accelerated
glycolysis in which lactate Ra far exceeds the capacity of
lactate Rd via oxidation, leading to profound lactate accumula-
tion in muscle and blood (lactatemia). Sustained muscular
power output depends on highly integrated processes
involving cardiopulmonary, cardiovascular, and muscle oxida-
tive capacities (Brooks, 2012, 2014). By way of comparison, a
healthy young woman or man with a VO2max of 3 L O2/min
with respiratory quotient (VCO2/VO2) z1.0 (indicting depen-
dence on carbohydrate [CHO] combustion) generates
15 kcal/min from oxidative metabolism. Because the body’s
efficiency of converting chemical to mechanical power approx-
imates 25% (Gaesser and Brooks, 1975), in the example pro-
vided the person could generate an external PO of z262 W
(assuming 1 kcal/min = 69.8 W) through cell respiration.
Unique individuals in the population with extraordinary levels
of VO2max (e.g., 5 L O2/min) can generate proportionately
higher levels of energy release (e.g., 20 kcal/min z1,400 W)
from cell respiration. Because training and experience do not
significantly affect muscle efficiency (Nickleberry and Brooks,
1996; San-Milla´n and Brooks, 2018), the external power output
from cell respiration in the example cited would be only 350 W.
However, we know from studies on athletes that they can
generate much higher muscle power output during short
periods of activity owing to the very high capacity for muscle
glycogenolysis and glycolysis (di Prampero, 2003; Driss and
Vandewalle, 2013; San-Milla´n and Brooks, 2018).
An example of sustained muscle activity in which glycolytic
flux was matched to lactate Rd without lactatemia is to be
found in a recent study on 22 International Cycling Union (ICU)
male Pro Tour cyclists. With VO2max normalized to body mass
of 74.1 ± 4.7mLO2/kg/min and amaximal exercise power output
of 378.5 ± 30 W, the Pro Tour cyclists could sustain exercise
power outputs R 300 W before significant lactatemia (San-
Milla´n and Brooks, 2018). In contrast, corresponding values in
moderately active, healthy young males were VO2max 49.6 ±
5.8 mL O2/kg/min and maximal leg power output 246.3 ± 26
W. Those men could generate only 125 W before lactatemia
occurred. Rephrased, healthy young men could not even briefly
achieve the muscle power output sustained by Pro Tour athletes
for hours on consecutive days for weeks. The point of this illus-
tration is that an individual’s ability to sustain glycolysis and
simultaneous lactate clearance without incurring hyperlactate-
mia is necessary for muscle power and endurance in athletics
and other endurance activities.
In contrast to the example of Pro Tour cyclists capable of
matching glycolytic flux and oxidative lactate disposal over sus-
tained periods is the example of power athletes. Power athletes
are capable of bursts of muscle power measured not in W, but in
kilowatts (kW) (di Prampero, 2003; Driss and Vandewalle, 2013).
During high-power activities, ATP and creatine phosphate (CP)
stores in muscle are readily and rapidly available but meager
(10–12 kcal) (Brooks et al., 2004). Oxygen stores in blood and
muscle combinedwith a few breaths of O2 consumption can pro-
vide some ATP, butmost energymust come fromglycogenolysis
and glycolysis. Proportions used by the three energy sources are
time dependent, with CP consumed in the first seconds and
energy contributions from glycolysis and cell respiration growing
in importance as duration extends. Because the half response
time for oxygen consumption approximates 30 s, the message
is that glycolysis is essential for high muscle power as in sprint
762 Cell Metabolism 27, April 3, 2018
Cell Metabolism
Review
activities. Glycolysis provides ATP directly by substrate level
phosphorylation of ADP and indirectly by providing lactate and
pyruvate as substrates for mitochondrial oxidative phosphory-
lation.
Body Fueling with Lactate Compared to Glucose
Compared to glucose flux that may increase 2–3 times in
humans during the transition from rest to exercise (Bergman
et al., 1999a; Emhoff et al., 2013b; Friedlander et al., 1997,
1998; Stanley et al., 1988), the capacity to increase lactate flux
is far more expansive, rising from a rate 50% of that of glucose
in a resting postabsorptive person to a value four times that of
the glucose flux during exercise (Bergman et al., 1999b; Brooks
et al., 1991a; Mazzeo et al., 1986; Stanley et al., 1985, 1986,
1988). In rodents with relatively high metabolic rates, lactate
flux can exceed glucose flux in resting animals, but again, the
many-fold gain in lactate over glucose flux is seen in the transi-
tion from rest to exercise (Brooks and Donovan, 1983; Donovan
and Brooks, 1983). In terms of fueling active tissues during exer-
cise, it is important to recognize that 80% or more of lactate is
disposed of via oxidation (Bergman et al., 1999b; Mazzeo
et al., 1986; Stanley et al., 1986). To a physiologist, the relatively
greater gain in lactate over glucose flux capacity is readily
appreciated because hepatic glycogenolysis and muscle
glycogenolysis rates are very low in resting postabsorptive
conditions (Ahlborg and Felig, 1982). However, despite a rise in
hepatic glycogenolysis supporting glucose Ra during exercise,
the massive increases in muscle glycogenolysis during exercise
(Bergstro¨m and Hultman, 1967; Hultman, 1967) give rise to
glycolysis and muscle lactate production (Bergman et al.,
1999b; Stanley et al., 1986) that dwarf the capacity for hepatic
and renal glucose Ra and muscle glucose uptake. This use of
lactate as a fuel requires mitochondrial respiration, and thus it
follows that an ability to rapidly utilize lactate (or any other
oxidation fuel) requires amplemitochondrial abundance and res-
piratory capacity. The body has evolved to couple lactate supply
and capacity for utilization through regulation of mitochondrial
biogenesis that is discussed below.
Mitochondrial Biogenesis and Lactate
Modern studies in physiology and biochemistry have shown that
remarkable plasticity of the mitochondrial abundance in
response to regular, endurance-type physical activity as well
as high-intensity interval training (HIIT) may double the mito-
chondrial mass (Davies et al., 1981; Holloszy, 1967; Kirkwood
et al., 1987; Robinson et al., 2017). Contemporary studies of
physiology and biochemistry have also revealed the molecular
signals for exercise-induced increases in mitochondrial protein
expression. Among the cellular signaling candidates for tran-
scriptional control of mitochondrial biogenesis are: calcium
ion (Ojuka et al., 2002), AMP-activated protein kinase (AMPK)
(Luo et al., 2005; Wadley et al., 2006), Sirtuin 1 (Sirt1) (Dumke
et al., 2009), and the ‘‘master mitochondrial biogenesis
activator,’’ peroxisome proliferator-activated receptor gamma
coactivator-1a (PGC-1a) (Handschin and Spiegelman, 2011).
Downstream regulators of mitochondrial biogenesis are:
nuclear respiratory factors 1 and 2 (NRF-1 and NRF-2) andmito-
chondrial transcription factor A (TFAM) (Nirwane andMajumdar,
2017). What these signaling pathways appear to share in
common are circumstances resulting from a challenge to ATP
homeostasis (Brooks, 2010, 2014, 2016).
While there has been major emphasis in studying downstream
effectors of mitochondrial biogenesis, scarce attention has been
placed on upstream effectors. For instance, Lezi and colleagues
in the Swerdlow lab (E et al., 2013) have shown that intraperito-
neal L-lactate administration to mice upregulates mitochondrial
protein expression in diverse tissues such as brain. This upregu-
lation of mitochondrial protein expression is perhaps best exem-
plified in the effort to identify how changes in Sirt1 activation
affect mitochondrial biogenesis. In diverse reports on SIRT 1,
activation was observed via changes in cell redox through
putative roles of the concentration of nicotinamide (NAM) and
the activity of enzyme NAMphosphoribosyl transferase (Nampt).
However, what is lacking is a comparison of how changes in
Nampt activity versus changes in glycolytic flux and attendant
lactate production and disposal can change cell redox in vivo.
Similarly, what is lacking is a comparison of how lactate produc-
tion and attendant changes in cytosolic redox in driver cells and
disposal in recipient cells affects the NAD+/NADH in various cell
compartments. Nominal [lactate] in cells is < 1.0 mM, but the
dynamic range in flux and concentration can be 20- to 30-fold
(Cheetham et al., 1986), with a corresponding dynamic L/P range
of 10 to > 500 (Henderson et al., 2007). The rise in blood L/P dur-
ing exercise is relatively larger than the relative rise in [lactate]
because the relative and absolute increments in [pyruvate] are
low compared the comparable changes in [lactate] (Henderson
et al., 2007; Wasserman et al., 1985). Interestingly, based on
simultaneously determined values of L/P in the venous effluent
from working muscle and arterial blood, it is evident that ratios
are much lower in arterial than in venous blood. These results
are attributable to pulmonary lactate clearance and indicate a
role for the lungs as a metabolic organ (Johnson et al., 2011,
2012). Regardless of relative or absolute changes in blood
lactate and pyruvate levels during a single circulatory passage,
the impactful role of lactate in cell-cell signaling is indicated by
the presence of millimolar changes in lactate concentration
and order-of-magnitude changes in L/P that are to be contrasted
with nano- or femtomolar changes in the concentrations of
transcription factors and coactivators in response to exercise
and other stresses.
Gluconeogenesis from Lactate
Because the majority of lactate disposal is directed toward
immediate oxidation, the bulk of the discussion on lactate
utilization above centered around oxidative disposal. However,
perhaps the first recognition of a metabolically beneficial use
of lactate in normal physiology was discovery of the Cori cycle,
with lactate as the major gluconeogenic precursor (Cori and
Cori, 1946). Indeed, in addition to acting as an oxidative fuel
source, lactate flux is metabolically beneficial through its supply-
ing carbon to gluconeogenesis. As typically rendered, the Cori
cycle is depicted as having intracellular lactate shuttles in both
muscle and liver that are linked via a cell-cell or rather an or-
gan-organ (muscle to liver) lactate shuttle. Although developed
on the basis of elegant studies on laboratory animals, due to
technical limitations the Coris, in fact, never demonstrated the
phenomenon in humans. Still, with contemporary isotope tracer
and arterial-venous difference measurements, it is certain that
glycemia is supported during postabsorptive (fasted) rest and
physical exercise (Bergman et al., 2000; Consoli et al., 1990;
Emhoff et al., 2013b; Friedlander et al., 1997, 1998; Jenssen
Cell Metabolism 27, April 3, 2018 763
Cell Metabolism
Review
et al., 1993; Woerle et al., 2003) and that hepatic gluconeogenic
function is augmented by the kidneys under diverse physiolog-
ical conditions (Meyer et al., 2002a, 2002b).
Lactate Shuttling in Postprandial Glycogen Repletion:
The ‘‘Glucose Paradox’’
The importance of lactate in intermediary metabolism is also
illustrated by its central role in the ‘‘glucose paradox.’’ In post-
absorptive conditions, lactate is the main gluconeogenic
precursor (Bergman et al., 1999a, 2000; Emhoff et al., 2013b;
Meyer et al., 2002a; Trimmer et al., 2002; Woerle et al., 2003).
However, the path of carbon from dietary cerebral carbohydrate
(CHO) to hepatic glucose and glycogen is indirect. After a CHO-
containing meal, a significant portion of glucose from digestion
bypasses the liver, and glycolysis and lactate production are
stimulated in peripheral tissues (e.g., muscle) (Brooks, 1997,
1998, 2012). Via muscle efflux and systemic delivery, lactate
provides the precursor for hepatic glycogen synthesis via the
‘‘indirect pathway’’ (Foster, 1984). The pathway is referred to
as ‘‘indirect’’ and ‘‘paradoxical’’ because some hepatic portal
glucose from CHO nutrition bypasses the liver and enters the
systemic circulation only to return as a precursor (lactate) for
glycogen synthesis. Estimates vary depending on species, but
the relative indirect pathway contribution to postprandial hepat-
ic glycogen synthesis in humans (z25%) (Woerle et al., 2003) is
less than in animal models, but still appreciable (Foster, 1984).
Hence, from the perspective of the indirect pathway of hepatic
glycogen synthesis, a rise in arterial blood [La!] following CHO
ingestion stimulates glyconeogenesis and the fraction of gluco-
neogenesis derived from lactate.
Brain Function, Cognition, and Lactate
As early as the 1950s, HenryMcIlwain had shown that lactate is an
efficient fuel for the brain ex vivo (McIlwain, 1953). This finding has
received decades of supporting evidence from Schurr and others
(Schurr andGozal, 2012; Schurr and Payne, 2007). On a net basis,
in resting, postabsorptive individuals, glucose is the preferred fuel
source for the brain. Net cerebral uptake (i.e., cerebral metabolic
rate, CMR) for glucose depends on cerebral blood flow (CBF) and
the arterial-venous [glucose] difference (CMRGlucose = (a!v)
Glucose (CBF)). In most cases, in resting individuals, delivery of
glucose to the brain (blood [glucose] approximating 5 mM and
180 g/mol) is large compared to the corresponding values for
lactate (blood [lactate] < 1.0 mM and 89 g/mol). Hence, in resting
postabsorptive individuals, lactate’s contribution to brain fueling
is low compared to glucose. For example, at a plasma [lactate]
of 1.0 mM, on a net basis, lactate contributes to 8%–12% of
the brain’s total energy requirement (Gallagher et al., 2009; Glenn
et al., 2015b). However, if one evaluates the importance of brain
fueling simply by considering net metabolite uptake, then the
role of lactate in brain fueling will not be appreciated. Two types
of cases appropriately describe the importance of lactate in brain
fueling; these examples are after traumatic brain injury (TBI) and
physical exercise by healthy individuals.
In comatose TBI patients, the role of lactate in brain fueling
was found to be impressive, as most (70%–80%) of circulating
blood glucose was produced via gluconeogenesis from
lactate (Glenn et al., 2015a, 2015b). As well, net lactate uptake
provided 12% of brain fuel. Hence, indirectly via gluconeogen-
esis (45%), plus directly (12%), most (57%) of brain fuel was
from lactate.
In healthy humans during exercise, plasma lactate levels can
increase an order of magnitude or more. For example, with a
10-fold rise in concentration, net lactate uptake provided 25%
of total brain energy need (Gallagher et al., 2009; van Hall
et al., 2009). Neglecting for a moment that cerebral disposal of
glucose is by conversion to lactate, preference of cerebral
lactate over glucose is seen in studies on rats (Smith et al.,
2003) and humans (Quistorff et al., 2008; van Hall et al., 2009),
and the provision of lactate to a healthy brain decreases glucose
net uptake. This observation indicates an important cerebral
lactate shuttling phenomenon. Alternatively, some might
consider that lactate can serve as an ‘‘alternative brain fuel.’’
However, as emphasized by Schurr, lactate is ‘‘the brain fuel’’
because whether extracellular glucose or lactate are taken up
by brain, the path of glucose disposal is through conversion to
lactate and a cell-cell lactate shuttle (Schurr, 2006; Schurr and
Payne, 2007).
In addition to serving as a cerebral energy substrate, circu-
lating lactate can signal secretion of cerebral brain-derived neu-
rotrophic factor (BDNF). As already discussed in part, circulating
blood lactate can be raised during exercise by production in
muscle, the integument, and other epinephrine-sensitive tissues.
As well, circulating lactate levels can be raised during rest or ex-
ercise by vascular L-lactate infusion into the systemic circula-
tion. Indeed, infused sodium lactate raises circulating BDNF
levels (Coco et al., 2013). BDNF is a member of the neurotrophic
family of proteins and facilitates neurogenesis, neuroprotection,
neuroregeneration, and synaptic plasticity as well as formation,
retention, and recall of memory (Seifert et al., 2010). BDNF is pro-
duced both in the central nervous system and in other tissues,
including the vascular endothelium. High levels of BDNF mRNA
are found in the hippocampus and in the cerebral cortex, and
in rodent models physical exercise is the strongest known stim-
ulus to BDNF expression in the hippocampus (Cotman and
Berchtold, 2002). In contrast, attenuated expression of BDNF
mRNA in the hippocampus may constitute a pathogenic factor
common to Alzheimer’s disease and major depression
(Tsai, 2003). Circulating BDNF is typically elevated in exercise,
but levels are reduced in patients with depression and type
2 diabetes (Krabbe et al., 2007). Even though acute exercise
increases BDNF production in the hippocampus and cerebral
cortex, studying the effects of exercise on BDNF expression in
the human brain is difficult. In what may become noted as a
classic study in neurochemistry, Seifert et al. (Seifert et al.,
2010) compared BDNF levels in arterial and internal jugular
vein blood and showed effects of exercise and exercise training
on cerebral BDNF net release.
While many posit a positive role for BDNF in terms of cogni-
tion, it is important to know also that lactate therapy has been
shown to raise BDNF levels and improve cognitive function in
rodent models following brain injury (Bisri et al., 2016; Holloway
et al., 2007; Rice et al., 2002). Most recently, in an extraordinary
set of experiments on healthy men who volunteered to exercise
at high intensities with arterial and jugular bulb catheters in
place, Hashimoto et al. (Hashimoto et al., 2018) showed that
executive function was directly correlated to blood [lactate]
and cerebral lactate uptake. Most recently, Wang et al. (Wang
et al., 2017) provided data that optogenetic activation of astro-
cytes in the anterior cingulate cortex (ACC) triggers lactate
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release and improves decision-making in rats with chronic
visceral pain. Hence, as predicted in papers from studies on
rodents (Schurr and Gozal, 2012; Wang et al., 2017) and healthy
and injured humans (Glenn et al., 2015b), Hashimoto et al. pro-
duced results that brain fueling with lactate improved cerebral
functioning. Additionally, with respect to cognition, it has been
shown that long-term memory consolidation in rat hippocam-
pus relies on lactate and the ANLS (Steinman et al., 2016; Suzuki
et al., 2011).
L- versus D-Lactate Enantiomer
The use of lactate-containing solutions and supplementation of
energy in clinical settings (i.e., hospital resuscitation fluids) will
be discussed later. However, before leaving this introductory
section, it is important to note that it is the L- (not the D-) lactate
enantiomer that possesses physiological action and efficacy for
energy supplementation and cell signaling in resuscitation fluids.
Several lines of evidence support this statement.
Early studies on transporter-mediated lactate movement
across plasma membranes clearly indicated Michaelis-Menten
kinetics and stereospecificity of L-lactate transport. In contrast,
exchange of D-lactate was far slower and did not follow
Michaelis-Menten kinetics or display other characteristics of
carrier-mediated transport (Garcia et al., 1994; Roth and
Brooks, 1990a, 1990b). As well, evidence points to L-lactate
as the effective enantiomer in fluid resuscitation (Boysen and
Dorval, 2014; Chan et al., 1994; de-Madaria et al., 2017). Addi-
tionally, L-lactate is the ligand for the putative lactate receptor
GPR81 that is expressed in brain, muscle, and adipose tissues
(Ahmed et al., 2010; Bergersen, 2015; Lauritzen et al., 2014). As
an aside to reappear later in this review, clinicians tend to use
either ‘‘normal’’ (0.9%) NaCl or Lactated Ringer’s (273 mOsm)
solutions for fluid resuscitation. However, while administration
of either is consistent with Standard of Care (SOC) fluid resusci-
tation, until recently it was unclear from the literature whether
one or the other solution results in superior patient outcomes
(de-Madaria et al., 2017). Rather, the selection of one solution
over the other seems more to do with tradition in clinical training
rather than laboratory or clinical science. Perhaps the absence
of clear superiority of Lactated Ringer’s solution compared to
normal saline has to do with inclusion of racemic mixtures
containing equal contents of D- and L-lactate enantiomers in
Lactated Ringer’s solutions?
Neither from the classic or contemporary literature nor
from vendor specifications on FDA-approved products is it
clear whether commercially approved and clinically used
Lactated Ringer’s solutions contain 100% L-lactate or a racemic
(50/50) mixture of L- and D-lactate, a disadvantage of the
D-lactate enantiomer, being that it is neurotoxic (Chan et al.,
1994). Although not FDA approved by virtue of extensive clinical
trials, in clinical experiments we (Miller et al., 2002a, 2002b,
2005) and others (Bouzat et al., 2014) have administered isotonic
(310 mM) and hypertonic (0.5 M) sodium L-lactate solutions
with good effects in published reports and ongoing clinical
trials (vide infra).
The Cell-Cell Lactate Shuttle: Initial Discovery
The initial impetus leading to recognition of the presence of a
‘‘lactate shuttle’’ came by means of an invitation from the
distinguished comparative physiologist Peter Hochachka to
participate in a symposium on ‘‘The Biochemistry of Exercise:
Insights fromComparative Studies’’ to be held in Liege, Belgium
in 1984. Recognition of the presence of lactate shuttling in
normal physiology has led to discovery of the presence of
several lactate shuttles. Piecing together recently published
data on glucose (Brooks and Donovan, 1983) and lactate
(Donovan and Brooks, 1983) fluxes in resting and exercising
trained and untrained rats with other data on lactate concentra-
tions and fluxes in mammals, the concept of a lactate shuttle
emerged. In terms of quantitation, lactate turnover and oxida-
tion in resting rats were surprisingly high, but typically less
than corresponding glucose flux rates. However, during exer-
cise lactate flux and oxidation easily exceeded glucose flux
rates. Moreover, during exercise most glucose production
came from lactate via gluconeogenesis (the Cori cycle). In terms
of the effects of training on carbohydrate metabolism, training
not only increased the capacity of gluconeogenesis, but training
had dramatic effects on lactate metabolic clearance rate (MCR
= disposal rate/concentration). The classic effect of exercise
training to lower blood lactate concentration was observed in
rats running on a motorized treadmill, but tracer data showed
that lactate production was high but balanced by disposal in
exercising trained rats, the lower circulating blood lactate
concentration being explained by greater clearance rates attrib-
utable to increased oxidation and gluconeogenesis of lactate
(Brooks and Donovan, 1983; Donovan and Brooks, 1983). Sub-
sequently, with the advent of stable, non-radioactive isotope
tracers, the same effects of training on glucose and lactate
turnover responses to exercise and exercise training were repli-
cated in cross-sectional (Emhoff et al., 2013a, 2013b; Mazzeo
et al., 1986; Stanley et al., 1985) and longitudinal training studies
on humans (Bergman et al., 1999a, 1999b, 2000).
Results of whole-body tracer studies are informative, but the
data provided no specific data on the tissue sites of lactate
production and disposal. However, in 1984 studies on tissue
specificity of lactate metabolism were underway (Bergman
et al., 1999b; Gertz et al., 1981; Stanley et al., 1986), and more
were to come later (Bergman et al., 1999a, 1999b; Gertz et al.,
1988). For example, in 1984 fueling of the heart during exercise
with lactate released from working muscle beds was observed
andwas key to envisioning a lactate shuttle. Aswell, from studies
by Paul Mole, Kenneth Baldwin, and their associates onmuscles
of lab rats made to exercise acutely and chronically (Hooker and
Baldwin, 1979; Mole´ et al., 1973), a lactate shuttle concept was
necessary to explain not only why lactate concentration in work-
ing red skeletal muscle was lower than that in white sections of
the same muscle, but also why lactate concentration in working
red skeletal muscle was lower than that in the blood perfusing it.
Thus, the concept of a lactate shuttle was born (Brooks, 1984)
and subsequently described more fully (Brooks, 1985, 1986). In
terms of cell-cell lactate shuttling, it was subsequently recog-
nized that red and white fibers exchange lactate within a tissue
bed and between tissue beds such as skeletal muscle and heart.
The beating heart takes up and oxidizes lactate (Bergman et al.,
2009; Gertz et al., 1981, 1988), as do working skeletal muscle
beds (Bergman et al., 1999b; Stanley et al., 1986), but what is
the path between lactate uptake and the formation and release
of CO2 from a tissue bed? Was there an intracellular lactate
shuttle?
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Intracellular Lactate Shuttles
The Cytosol-to-Mitochondrial Lactate Shuttle and
Mitochondrial Lactate Oxidation Complex (mLOC)
Historically, many believed that the liver and kidneys are the ma-
jor organs of lactate disposal via gluconeogenesis (Cori andCori,
1946) and conversion to bicarbonate (e.g., https://dailymed.nlm.
nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=2425),
evidence for the purported conversion of lactate to bicarbonate
in the liver being nil. In contrast, studies on humans (Mazzeo
et al., 1986; Stanley et al., 1985) and other mammals (Depocas
et al., 1969; Donovan and Brooks, 1983; Freminet et al., 1974) re-
vealed that most lactate was disposed of via oxidation (to CO2,
with bicarbonate formed simply as the result of CO2 reacting
with water in an equilibrium reaction catalyzed by carbonic anhy-
drase). Lactate disposal via oxidation was particularly prominent
whenmuscles were engaged. With that realization, issues arose:
where in a working muscle, heart, or other tissue or cells was
lactate oxidized? Much thinking was that the first step in lactate
oxidation to pyruvate occurred in the cytosol, but for several rea-
sons that idea made no sense. Beating heart (Gertz et al., 1981)
and working red muscle (Stanley et al., 1986; Zinker et al., 1993)
simultaneously consume glucose and take up and oxidize
lactate. To reiterate, in arterial blood of a resting person, the
lactate-to-pyruvate ratio (L/P) ranges from 10 (Henderson
et al., 2007) to 20 (Wasserman et al., 1985); however, when mus-
cles contract to achieve a moderate exercise power output, the
L/P in venous blood effluent of working muscle rises more than
an order of magnitude (i.e., L/P > 500) (Henderson et al., 2007).
Because of the presence of LDH in erythrocytes and lung paren-
chyma (Johnson et al., 2011, 2012), relative rise of the L/P in arte-
rial blood of exercising individuals is significant but blunted
(Bergman et al., 1999b; Henderson et al., 2007; Wasserman
et al., 1985). Given these data, the notion that lactate oxidation
occurs in the cytosol is implausible. If not in the cytosol, where
then does lactate oxidation commence? Where else but in the
mitochondrial reticulum!
The thought process that lactate oxidation occurred in mito-
chondria stemmed from work using the classical enzymatic
lactate analysis utilizing LDH (Gutmann and Wahlefeld, 1974).
Realizing that the Keq for LDH approximated 1,000, thus favoring
the reduction of pyruvate to lactate and making lactate oxidation
to pyruvate unlikely, Gutmann utilized hydrazine to trap pyruvate
as hydrazone, thus keeping the concentration of pyruvate very
low and allowing LDH to work against its natural equilibrium
and oxidize pyruvate to lactate, an NAD+/NADH-linked reaction,
and allowing spectrophotometric detection. Hence, the pyruvate
and lactate assays were similar, except that the assay for lactate
contained hydrazine whereas the assay for pyruvate did not
(Gutmann and Wahlefeld, 1974). With that knowledge, the anal-
ogous model became that the mitochondrial reticulum served as
the pyruvate trap allowing mitochondrial LDH to oxidize lactate
to pyruvate that would subsequently be rapidly cleared by
PDH to keep pyruvate levels low and resulting in oxidation in
the TCA cycle. This idea presupposed that the mitochondrial re-
ticulum could oxidize lactate and that the reticulum contained an
MCT and LDH, as well. It turned out that the model is correct.
The Mitochondrial Lactate Oxidation Complex (mLOC)
The discovery that mammalian mitochondrial preparations
oxidize lactate has been controversial; some investigators can
produce such preparations (Baba and Sharma, 1971; Brandt
et al., 1987; Brooks et al., 1999a; De Bari et al., 2004; Kline
et al., 1986; Passarella et al., 2014), whereas some (Rasmussen
et al., 2002; Sahlin et al., 2002; Yoshida et al., 2007) cannot. With
clear demonstration of lactate oxidation in mitochondrial prepa-
rations from human skeletal muscle (Jacobs et al., 2013) along
with supportive data from magnetic resonance spectroscopy
(MRS) (Chen et al., 2016; Park et al., 2015), perhaps the issue
of mitochondrial lactate oxidation has been resolved? Difficulties
in obtaining vesicular mitochondrial preparations from mamma-
lian tissues likely have to do with disruption of the mitochondrial
reticulum (Glancy et al., 2017; Kirkwood et al., 1986) during isola-
tion and labiality and fragility of the L-lactate dehydrogenase
during isolation of mitochondrial vesicles. Loss of a mitochon-
drial preparation’s (Boussouar and Benahmed, 2004) capacity
to respire lactate is not unique, as a similar problem with oxida-
tion of long-chain fatty acids has been ascribed to use of the
proteolytic enzyme Nagarse to increase mitochondrial protein
yield, but the resulting preparations lose the ability to oxidize
fatty acids or their carnitine derivatives (Pande and Blanchaer,
1970). In this instance the inability of mitochondria preparations
to recapitulate what is known to happen in vivo can be ascribed
to isolation artifact. Similarly, the ability or inability of mitochon-
drial preparations to oxidize exogenous lactate may be attrib-
uted to isolation artifact. Obviously, more work on issues related
to mitochondrial isolation artifacts and the intracellular sites of
lactate oxidation is required.
To the point, tissue lactate production, uptake, and oxidation
occur because glycolysis and mitochondrial respiration occur
simultaneously in vivo. For the mitochondrial reticulum to oxidize
lactate, the reticulum must contain a transporter (Brooks et al.,
1999a; Butz et al., 2004) and LDH (Baba and Sharma, 1971;
Hashimoto et al., 2006), both of which were found as soon as
probed for and are now listed in mitochondrial constituent
databases such as MitoCarta (Calvo et al., 2016; Pagliarini
et al., 2008) and MitoMiner (http://mitominer.mrc-mbu.cam.ac.
uk/release-4.0/begin.do).
In terms of functionality, the mLOC (Figure 4) contains several
essential components of lactate oxidation: an MCT, its mem-
brane chaperone basigin (BSG or CD147), LDH, and cytochrome
oxidase (COx), as seen in muscle (Hashimoto et al., 2006), liver
(De Bari et al., 2004; Passarella et al., 2014), brain (Hashimoto
et al., 2008), and various model systems such as brain slices
(Schurr, 2008), primary neuronal cultures (Atlante et al., 2007;
Hashimoto et al., 2008), normal breast and transformed breast
cancer cells (Hussien and Brooks, 2011), and tumors (Sonveaux
et al., 2008). But why does the model (Figure 4) not emphasize a
role for the mitochondrial pyruvate carrier (mPC)? The answer is
that definitive data are not available on spatial and functional
interactions between mPCs and mMCTs and the role of mPCs
in mitochondrial lactate oxidation.
Following reports of discovery of themPC (Bricker et al., 2012;
Herzig et al., 2012), and with access to our own custom anti-
bodies to MCT1 as well as commercially available antibodies
to the putative mPC, we obtained images assessing colocaliza-
tion of MCT1 and mPC in L6 cells. In those preliminary studies,
colocalization analysis of mMCT1 and mPC1 in Imaris software
showed an r2 of 0.8. It appears that both MCT1 and mPC are
co-localized to the mitochondria (r2 = 0.8). However, at the light
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microscopic level, it is impossible to know if mMCT and mPC
interact physically and functionally. Immunocoprecipitation,
X-ray crystallography, mass spectrometry, and deletion studies
are needed to definitively answer questions about mMCT and
mPC colocalization and functionality and role of themPC inmito-
chondrial lactate oxidation.
And finally, with regard to the site of intramitochondrial lactate
oxidation to pyruvate, in an attempt to integrate ideas about the
place of mPCs in mitochondrial morphometry (Divakaruni and
Murphy, 2012), Gladden and associates (Rogatzki et al., 2015)
modified Figure 4 to include a role for the mPC in mitochondrial
lactate oxidation. That decision led to the hypothesis that mito-
chondrial lactate oxidation to pyruvate occurred in themitochon-
drial inter-membrane space, but that conclusion is inconsistent
with what we (Hashimoto et al., 2008; Hussien and Brooks,
2011) and others (Atlante et al., 2007; De Bari et al., 2004;
Passarella et al., 2014) have found concerning the location of
mitochondrial LDH.
Results of future research efforts to better define mitochon-
drial lactate and pyruvate oxidation complexes are greatly antic-
ipated. Nonetheless, at present it is possible to conclude that the
mitochondrial reticulum contains mechanisms to oxidize pyru-
vate and lactate as depicted in Figures 3 and 4.
By way of completeness, credit for use of the term ‘‘lactate
shuttle’’ needs to be attributed to Nobuhisa Baba and Hari M.
Sharma (Baba and Sharma, 1971), who in 1971 published histo-
logical evidence of LDH in rat heart and pectoralis muscle. In ex-
plaining the potential significance of their findings, they postulated
the presence of a lactate shuttle. I discovered the 1971 reference
after the same realization and years of research on the subject. In
response to a letter of inquiry, asking why the shuttle hypothesis
was not pursued, Nobuhisa Baba indicated that clinical responsi-
bilities precluded further investigation.
The Peroxisomal Lactate Shuttle and b-Oxidation
Peroxisomes are cellular organelles found in virtually all eukary-
otic cells that are involved in catabolism of substances such as
very-long-chain (i.e., C22 and longer) fatty acids, branched-
chain fatty acids, D-amino acids, poly amines, and reactive oxy-
gen species such as hydrogen peroxide (H2O2) (Gladden, 2004).
While it was known that b-oxidation of very-long-chain fatty
acids occurred in mammalian peroxisomes (Lazarow and De
Duve, 1976), in the absence of enzyme systems as exist in the
mitochondrial matrix, it was not understood how b-oxidation
could occur in peroxisomes. Key findings were that of Baumgart
et al. (Baumgart et al., 1996), who showed the presence of
peroxisomal LDH isoforms, and McClelland et al. (McClelland
et al., 2003), who confirmed the presence of LDH and further
demonstrated that rat liver peroxisomal membranes contained
MCT1 and MCT2. From there it was possible to hypothesize
that peroxisomal redox control necessary to support b-oxidation
involved a lactate-pyruvate shuttle.
Other than demonstrating the presence of peroxisomal LDH
(pLDH) and MCTs (pMCT), additional key findings were that
peroxisomal redoxwas affected by the addition of exogenous py-
ruvate or the LDH inhibitor oxamate. Aswell, the addition of exog-
enous pyruvate gave rise to peroxisomal lactate production and
efflux, and further, pyruvate-stimulated peroxisomal b-oxidation
was inhibited by the MCT blocker, a-cyano-4-hydroxycinnamate
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Figure 4. Mitochondrial Lactate Oxidation Complex
A schematic showing the putative mitochondrial lactate oxidation complex (mLOC): MCT1 is inserted into the mitochondrial inner membrane, strongly interacting
with its chaperone protein CD147, and is also associated with COx as well as mitochondrial LDH (mLDH), which could be located at the outer side of the inner
membrane. Lactate, which is always produced in cytosol of muscle and other tissues because of the abundance, activity, and characteristics of cytosolic LDH, is
oxidized to pyruvate via the lactate oxidation complex in mitochondria of the same cell. This endergonic lactate oxidation reaction catalyzed bymLDH, is coupled
to the exergonic redox change in COx during mitochondrial electron transport. GP, glycerol phosphate; Mal-Asp, malate-aspartate; ETC, electron transport
chain; MCT, monocarboxylate (lactate) transporter; mPC, mitochondrial pyruvate carrier; mLDH, mitochondrial lactate dehydrogenase; TCA, tricarboxylic acid
cycle. Redrawn from Hashimoto et al., 2006.
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(CINN) (McClelland et al., 2003). Discovery of the peroxisomal
lactate shuttle involving pyruvate-lactate conversion linked to
changes in the NADH/NAD+ redox couple emphasizes the critical
importance of redox changes in all forms of lactate shuttles.
Other Lactate Shuttles and Other Roles of Lactate
Since recognition of the presence of lactate shuttling within and
among various cells, tissues, and organs such as muscle, heart,
and liver (Brooks, 1984, 1985, 1986, 2002), the concept has been
extended to include other cells, tissues, and organs such as
brain (Liu et al., 2017; Pellerin et al., 1998), lung (Johnson et al.,
2011, 2012), sperm (Boussouar and Benahmed, 2004; Storey
and Kayne, 1977), adipose (Ahmed et al., 2010; Cai et al.,
2008; Liu et al., 2009), and peroxisomes (McClelland et al., 2003).
Astrocyte-Neuron Lactate Shuttle
Lactate shuttling between astrocytes and neurons was linked
to glutamatergic signaling by Pellerin and colleagues in 1994
(Pellerin andMagistretti, 1994), but the significance of the findings
and use of the term ANLS was to come some years later (Magis-
tretti et al., 1999). Since its introduction and further exposition
(Pellerin andMagistretti, 2012), the concept has remained contro-
versial (Patel et al., 2014). However, realizing that lactate has
autocrine-, paracrine-, and endocrine-like functions, the question
should be, ‘‘How can there not be an ANLS?’’ Elegant studies,
e.g., Pellerin et al., 2005, support the supposition that an ANLS
was operant. However, while cerebral lactate flux may be related
to glutamatergic signaling (Pellerin and Magistretti, 1994), there is
no reason to suppose that other cerebral processes do not partic-
ipate in lactate shuttling. For instance, in health and after injury,
the brain takes up and oxidizes lactate from the systemic circula-
tion (Glenn et al., 2015b) just as it does during physical exercise
(Hashimoto et al., 2018; vanHall et al., 2009). In such cases,meta-
bolism is more accurately described as a tissue-tissue, as
opposed to a cell-cell (i.e., astrocyte-neuron) lactate shuttle.
Regardless, the lactate shuttle concept holds true and explains
the exchange between lactate producer (driver) and lactate
recipient (consumer) cells in tissue-tissue and cell-cell lactate
shuttles in brain, and elsewhere (Figure 1B).
Because characteristics of cellular lactate uptake such as
stereospecificity, concentration and pH dependence, saturation,
and inhibition by competitive and non-competitive inhibitors
were recognized (Roth and Brooks, 1990a, 1990b; Watt et al.,
1988) even before MCT isoforms were cloned and sequenced
(Garcia et al., 1994, 1995; Price et al., 1998), it has been
appreciated that while MCTs facilitate movement of monocar-
boxylates such as lactate, pyruvate, and acetoacetate across
biological membranes, MCTs do not create the conditions for
lactate exchange; rather, driver processes such as glycolysis
and glycogenolysis give rise to lactate production, whereas
recipient processes such as mitochondrial respiration and
gluconeogenesis are responsible for lactate disposal (Brooks,
1984, 2002). Rephrased, MCTs facilitate lactate transport
down concentration and pH gradients. In this context of
hydrogen ion- and lactate anion-driven lactate flux, cerebral
lactate exchange can be appreciated. Just as lactate release
from working muscle (Stanley et al., 1986) can fuel the beating
heart (Gertz et al., 1988), so too canworkingmuscle fuel the brain
(van Hall et al., 2009), an ANLS not being necessary to explain
cerebral lactate metabolism as there is no obligatory role for
astrocytes to generate lactate for consumption by neurons
(Schurr, 2008). Examination of the cell type indicates that neu-
rons possess the apparatus necessary for lactate production
and release (Hashimoto et al., 2008) independent of an ANLS.
Still, discovery of the ANLS has advanced the field of lactate
shuttles substantially by providing a mechanism to describe
cerebral physiology such as memory formation.
Lactate Shuttling and Lipolysis in Adipose
An inverse relationship between blood [La!] and plasma free
fatty acid concentration [FFA] and oxidation has long been
recognized (Brooks and Mercier, 1994), but the associations
are underappreciated. In the 1960s Bella Issekutz and
colleagues noted the effect of lactacidemia on diminishing
circulating [FFA] in individuals during hard exercise (Issekutz
and Miller, 1962; Rodahl et al., 1964), and lactate infusion into
running dogs caused circulating [FFA] to decline (Gold et al.,
1963; Issekutz and Miller, 1962; Miller et al., 1964). In their
work these investigators could clearly observe an effect of the
lactate on circulating [FFA], but whether the mechanism was
an inhibition of lipolysis or a stimulation or re-esterification was
not addressed.
Recently, several groups of investigators (Ahmed et al., 2010;
Cai et al., 2008; Ge et al., 2008; Liu et al., 2009) have shown that,
independent of pH or sodium ion, lactate inhibits lipolysis in fat
cells through activation of an orphan G protein-coupled receptor
(GPR81) (Figure 5). Inmouse, rat, and human adipocytes, GPR81
appears to act as a lactate sensor with the inhibitory effect
on lipolysis operating through cyclic-AMP (cAMP) and cAMP
response element binding (CREB) (Bergersen, 2015; Hoque
et al., 2014; Lauritzen et al., 2014).
Beyond a role in inhibiting lipolysis, lactate also plays an impor-
tant role in limiting inflammation following injury. Consequently,
lactate-containing solutions are being evaluated as anti-inflam-
matory resuscitation fluids for use in a variety of other therapies
including acute pancreatitis (Hoque et al., 2014; Wu et al.,
2011), hepatitis (Hoque et al., 2014), and dengue fever (Somasetia
et al., 2014). Compared to normal saline, lactate-containing
resuscitation solutions offer the advantage of providing calories
as well as fluid and electrolytes. However, not until Hoque and
colleagues (Hoque et al., 2014) found that lactate binding to
GPR81 negatively regulates Toll-like receptor induction of the
pyrin domain-containing protein 3 (NLRP3) inflammasome and
production of IL-1b, via arrestin beta 2 (ARRB2) and GPR81,
was the mechanism by which lactate suppressed inflammation
in patients with acute organ injury understood.
In summary on this section, since the initial publication of Wu
and colleagues (Wu et al., 2011), the anti-inflammatory effects of
L-lactate therapy have been confirmed for several conditions
including treatment of uterine inflammation during contractions
(Madaan et al., 2017). Most recently, the work of de-Madaria
et al. (2017) has been noteworthy because they identified the
role of the L-lactate anion in Lactated Ringer’s solution in the
treatment of acute pancreatitis.
Lactate and Pyruvate as Inhibitors of Mitochondrial
b-Oxidation
When glycolysis is accelerated duringmuscle contraction, lactate
(L) and pyruvate (P) concentrations raise the lactate/pyruvate
ratio, or L/P. At rest, the L/P in muscle and venous effluent from
a muscle bed approximates 10, but the ratio rises more than an
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order of magnitude during moderate-intensity exercise (Hender-
son et al., 2004). Bymass action themonocarboxylate pair floods
into the mitochondrial reticulum (Brooks et al., 1999b; Passarella
et al., 2008; Saddik et al., 1993), giving rise to acetyl-CoA and
thereby malonyl-CoA formation (Figure 5). The rise in malonyl-
CoA inhibits the entry of activated FFAs into the mitochondrial
matrix by inhibiting carnitine-palmitoyl transferase-1 (CPT1)
(McGarry et al., 1977; Saddik et al., 1993) (Figure 5). As well,
the accumulation of acetyl-CoA could downregulate b-ketothio-
lase, the terminal and rate-limiting enzyme of the mitochondrial
b-oxidation pathway.
Spermatogenic and Sertoli-Germ Cell Lactate Shuttles
The concept of spermatogenic lactate shuttles was introduced
by L. Bruce Gladden in his classic review paper (Gladden,
2004). Gladden’s review unified extant data in the literature
and anticipated subsequent results in the field of fertility so
important for human reproduction, veterinary medicine, and
animal husbandry agriculture (Boussouar and Benahmed,
2004; Reynolds et al., 2017). Gladden’s treatment of the subject
has stood the test of time even as the technologies, including
magnetic resonance spectroscopy (MRS), have become more
sophisticated (Reynolds et al., 2017).
For decades it has been known that mammalian spermatozoa
can use lactate as an aerobic energy source (Storey and Kayne,
1977). Noteworthy also is that in their seminal papers on discov-
ery of MCT1 and MCT2, Garcia et al. noted high expression of
MCT1 in sperm heads as they entered the epididymis, followed
by lower expression of MCT1 expression as sperm coursed
through the epididymis (Garcia et al. 1994, 1995). Earlier it was
noted that lactate stimulates respiration in ejaculated bovine
sperm (Halangk et al., 1985), and further, lactate maintains
bovine spermmotility as well as glucose when sperm are studied
or maintained ex vivo (Inskeep and Hammerstedt, 1985). More
relevant to physiology is that just like fast twitch-glycolytic driver
muscle fibers that fuel slow twitch-oxidative muscle fibers,
Sertoli cells in testes secrete lactate, not glucose, to fuel sperm
motility in vivo. In effect, then, the Sertoli-sperm cell relationship
is the primal demonstration of cell-cell lactate shuttling. The Ser-
toli-sperm cell relationship is accompanied by an intracellular
lactate shuttle in vivo. In fact, the subtitle to the 1977 paper by
Storey and Kayne is ‘‘Direct intramitochondrial lactate oxidation
by rabbit sperm mitochondria’’ (Storey and Kayne, 1977). In
sperm, the mitochondrial reticulum is elaborate, large, and spiral
shaped, located at the midpiece, at the base of the sperm head.
In their ability to oxidize exogenously supplied lactate, the mito-
chondrial network is fueled as are mitochondria isolated from
other tissues as described above (Baba and Sharma, 1971;
Brandt et al., 1987; Brooks et al., 1999a; De Bari et al., 2004;
Kline et al., 1986). And, just as in mitochondria isolated from
other tissues, lactate is the preferred fuel for spermmitochondria
(Jones, 1997).
With regard to the presence of a mitochondrial lactate oxida-
tion complex in the mitochondrial reticulum in sperm, existing
data are supportive. For instance, with mitochondrial prepara-
tions from boar spermatozoa, external NADH was oxidized in
the presence of external lactate, but this oxidation was inhibited
by the MCT inhibitor a-cyano-4-hydroxycinnamate (Roth and
Brooks, 1990a, 1990b) and by oxamate, an inhibitor of LDH
Figure 5. Central Role of Lactate Influencing
Energy Substrate Partitioning
Illustration of how lactatemia affects blood [glucose] and
peripheral glucose uptake as well as the production,
uptake, and oxidation of FFA, giving rise to metabolic
inflexibility in muscle. Lactate is the inevitable conse-
quence of glycolysis (Rogatzki et al., 2015), the minimal
muscle L/P being 10 and rising to an L/P > 100 when
glycolytic flux is high (Henderson et al., 2007). Lactate is
the favored oxidizable substrate and provides product
inhibition of glucose and FFA oxidation. As the products
of glycolysis, lactate and pyruvate provide negative
feedback inhibition of glucose disposal (blue dashed
lines). Also, as the predominant mitochondrial substrate,
lactate gives rise to acetyl-CoA, and in turnmalonyl-CoA.
Acetyl-CoA inhibits b-ketothiolase and hence b-oxida-
tion, while malonyl-CoA inhibits mitochondrial FFA-de-
rivative uptake via CPT1 (T) (Saddik et al., 1993). More-
over, lactate is the main gluconeogenic precursor raising
glucose production, raising blood [glucose] (red lines).
Via GPR81 binding, lactate inhibits lipolysis in WAT (T),
depressing circulating [FFA] (Hoque et al., 2014; Liu
et al., 2009). This model explains the paradoxical pres-
ence of lactatemia in high-intensity exercise and insulin-
resistant states with limited ability to oxidize fat (green
lines). Modified from Hashimoto et al. (Hashimoto et al.,
2008). CPT1, carnitine palmitoyl transporter-1; FFA, free
fatty acid; FAT, fatty acid translocator comprised of
CD36 and FABPc; GLUT, glucose transporter; s, sarco-
lemmal; m, mitochondrial; malonyl, CoA formed from
exported TCA citrate controlled by the interactions of malonyl-CoA decarboxylase (MCD) and acetyl-CoA carboxylase (ACC); MCT, monocarboxylate trans-
porter; mPC,mitochondrial pyruvate transporter; PDH, pyruvate dehydrogenase; WAT, white adipose tissue; (T), inhibition. Not shown is fatty acyl-CoA (FA-CoA)
that will accumulate if FFAs are taken up by myocytes but blocked frommitochondrial entry by the effect of malonyl-CoA on CPT1. Accumulated intracellular FA-
CoA will give rise to intramyocellular triglyceride (IMTG) and the formulation of LC-FA, DAG, and ceramides via inhibition of phosphatidylinositol 3-kinase (PI3K)
and reducing GLUT4 translocation.
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(Brooks et al., 1999c; Calvin and Tubbs, 1978). Noteworthy is
that while oxamate blocks oxidation of lactate, pyruvate oxida-
tion is, if anything, enhanced (Brandt et al., 1987). Thus as in
mitochondrial preparations from other mammalian tissues
(Brooks et al., 1999a; Butz et al., 2004), both MCT and LDH
are required for the oxidation of lactate by sperm mitochondrial
preparations. Those results on boar sperm mitochondria were
supported by results on sperm mitochondria from rats and rab-
bits (Gallina et al., 1994). To be complete, it should be noted that
although available data support the presence of a lactate shuttle
in mitochondria from boars, rats, rabbits, and cattle, the lactate
shuttle is not likely present in mouse spermatozoa (Gallina
et al., 1994), and both lactate and malate-aspartate shuttles
are present in spermatozoa of many species (Calvin and Tubbs,
1978), which is common in cells of many tissues from diverse
mammalian species.
Lactate Shuttling in and out of the Gut Microbiome:
A Gut-Soma Lactate Shuttle?
Functional roles for the gut microbiome and its role in health and
disease are currently of significant interest (Turnbaugh et al.,
2007), with preliminary data indicating relationships between
microbiota and the prevalence of chronic diseases such as insu-
lin resistance and metabolic syndrome (Vrieze et al., 2012). One
of the underdeveloped areas of study concerns the role of lactate
and other products of fermentation in promoting health of the gut
mucosa. For example, inspired by findings on the role of lactate
as a signaling molecule, investigators have observed lactate to
downregulate pro-inflammatory responses in intestinal epithelial
and myeloid cells (Iraporda et al., 2015). The same group has
also observed anti-inflammatory effects of lactate in studies
using a 2,4,6-trinitrobenzenesulfonic acid (TNBSP) model of
induced colitis (Iraporda et al., 2016). Consequently,
Iraporda and colleagues advocate for the consumption of
lactate-containing foods for their favorable effects on the gut
microbiota in general (Iraporda et al., 2014) and specifically for
their potential role in protecting against intestinal pathogens
such as Salmonella (Iraporda et al., 2017).
As was typical of other areas of investigation, to date, studies
of gut lactate production and routes of disposal in the gut have
been limited by the lack of flux (turnover) measurements. Lactate
is a natural fermentation product, but little lactate appears in the
feces (Flint et al., 2015). To some this might mean that lactate is
unimportant for natural gut function, but an alternative view is
apparent. This is that there is high turnover (appearance and
disposal) of gut lactate. Lactate is a common end product of
bacterial fermentation and is produced by many phyla of
bacteria, in particular by lactic acid bacteria of the genera
Lactobacillus and Bifidobacterium. Because of their purported
health-promoting effects, these two genera are considered key
members of the gut microbiota (Hill et al., 2014).
Lactate can appear in the gut via the consumption of probiot-
ics such as fermented foods that, if eaten raw, contain live cul-
tures of lactate-producing bacteria. Examples of fermented
foods are kefir, yogurt, sauerkraut, pickles, miso, kimchi, and
sourdough breads. In addition to consumption of fermented
foods, lactate can appear in the gut as a dietary supplement,
such as in a sports drink (Azevedo et al., 2007). Efficacy of
providing lactate polymers and esters in in sports drinks and
other dietary supplements is possible because rapid lactate
uptake in the upper intestine is mediated by a sodium-lactate-
mediated transporter (SMCT) (Coady et al., 2004; Teramae
et al., 2010).
Lactate can also appear in the gut as the result of the con-
sumption of prebiotic, fiber-containing foods that promote
fermentation in the gut. Fibrous vegetables that function as pre-
biotics include asparagus, leeks, onions, grains, legumes, and
cruciferous vegetables such as broccoli, brussels sprouts,
cabbage, cauliflower, collard greens, kale, radish, and rutabaga.
In the colon, Lactobacillus, Bifidobacterium, and Firmicutes
ferment products of many fiber-containing carbohydrate foods
to pyruvate and lactate. From there, lactate (2-hydroxy-propio-
nate) is converted to propionate through the arcylate pathway
by Coprococcus catus and Megasphaera species (Veillonella-
ceae). As well, lactate can be converted to acetate and butyrate
by the CoA pathway through actions of several bacterial genera
including Eubacterium rectale and Coprococcus catus. Alterna-
tively, lactate can be converted to propionate by the succinate
pathway by Bacteroidetes (Veillonella species Dialister succina-
tiphilus and Phascolarctobacterium succinatutens) bacteria. In
terms of healthy gut function, butyrate, acetate, propionate,
and succinate, but not lactate, are considered to be helpful sub-
strates supporting metabolism in gut microbiota (Flint et al.,
2015; Galland, 2014). But why has a potential role for lactate
not been considered along with other monocarboxylates? Is his-
torical, unconscious bias to be considered?
Production of lactate in the lower gut by Lactobacillus and
Bifidobacterium and disposal via production and subsequent
metabolism of butyrate, propionate, and succinate may be one
reason why [lactate] is low in stool. Another, unstudied mecha-
nism may be that of lactate release into systemic circulation
via SMCTs (Coady et al., 2004; Teramae et al., 2010). Hints of
gut lactate production within and release from the GI tract with
disposal in other organs (i.e., a ‘‘gut-to-soma’’ lactate shuttle
mechanism) may be found in the postprandial rise in blood
L-lactate following CHO nutrition and presence of the indirect
(glucose paradox) pathway (vide supra). Another clue is that in
ex vivo studies of fermentation products from the action of gut
microbiota on apple and beet fibers, 72-hr lactate accumulation
was comparable to that of butyrate (Aguirre et al., 2014). And
perhaps an even more profound hint supporting the presence
of a gut-to-soma lactate shuttle may be that the gut releases
D-lactate in feces (Galland, 2014). Because it is likely that gut
microbiota produce a racemic (L- and D-lactic acid) mixture,
and also because it is likely that the L-lactate enantiomer is
metabolized in the gut and elsewhere, an accumulation of gut
D-lactate is to be expected. However, accumulation of D-lactate
could result in acidosis and irritation of the lower bowel. Further,
release of D-Lactate into circulation could have neurotoxic
effects (Chan et al., 1994; Galland, 2014; Thurn et al., 1985).
Given the developing database on D-lactate formation and its
toxic effects, it is not surprising that fecal transplantation has
been tested as a treatment for D-lactic acidosis in a child
with short bowel syndrome (Davidovics et al., 2016) and that
‘‘D-lactate free’’ probiotic products are being commercialized
(e.g., http://organic3.com/supplements/probiotics/d-lactate-
free-probiotics/).
To reiterate from above, it is likely that there is a very high turn-
over of L-lactate in the bowel that is not apparent using current
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methods of investigation. However, considering the idea of
simultaneous lactate production and utilization in the bowel, as
well as some lactate release from the bowel into systemic circu-
lation via SMCTs with disposal elsewhere in the body (i.e., a gut-
soma lactate shuttle), interpretation of extant data is different
from current ideas concerning the role of the microbiome in
health and disease. Rather than the specific bacterial load itself,
practices and mechanisms that promote the presence of gut
lactate may be more important. For instance, the consumption
of lactate-containing foods (Garrote et al., 2015) and gut fermen-
tation that support gut lactate synthesis and accumulation can
be important for gut health. Gut lactate not only supports integ-
rity of gut mucosa, but also likely results in an intestinal environ-
ment that can sustain a number of different combinations of gut
microbiota (Gilles, 2017).
An Organism-to-Organism Lactate Shuttle in Host-
Pathogen Interactions?
Based on our research (Weilhammer et al., 2012), the question
arose: can lactate shuttling occur across individuals and species
as occur in host-pathogen interactions? Toxoplasma gondii is an
obligate intracellular protozoan parasite of the phylum Apicom-
plexa. One of themost widespread parasites, T. gondii can infect
a wide range of warm-blooded host species, including approxi-
mately one-third of the world’s human population in both devel-
oped and developing countries (Tenter et al., 2000). The asexual
life cycle of T. gondii within non-feline (intermediate) hosts
involves conversion between two distinct forms: tachyzoites
and bradyzoites. Tachyzoites are the fast-replicating form
responsible for flu-like symptoms experienced during acute
infection. During the course of infection, tachyzoites differentiate
into bradyzoites, which are the slow-replicating form responsible
for establishment of long-lived tissue cysts that persist during
chronic infection. While tachyzoites can infect and replicate
within virtually any nucleated cell, bradyzoite cysts are typically
found within neural and muscle tissue (Weilhammer et al., 2012).
The sexual life of T. gondii occurs in cats that become infected
from the ingestion of infected rodents and birds.Within intestines
of infected cats, zygote-containing cysts are known as oocysts.
When oocysts rupture, T. gondii is shed in cat feces. Although
bradyzoite-containing tissue cysts can form in virtually any organ
of intermediary hosts, tissue cysts predominantly form and
persist in the brain, eyes, and striatedmuscle including the heart.
Humans become infected from the consumption of inadequately
cooked or cured meats of infected animals.
To evaluate the factors that regulate the stage conversion of
parasites from tachyzoites into bradyzoites in host cells,
Weilhammer et al. developed an in vitro system to evaluate resis-
tance of different cell types to tachyzoite-bradyzoite conversion.
By evaluating metabolic responses in infected host cells as well
as media from infected cells, Weilhammer et al. (Weilhammer
et al., 2012) identified that induction of glycolysis leading to
lactate production was protective for conversion.
Their hypothesis was studied in several ways, including
glucose incubation, identification of lactate as the protective
component in incubation media, pharmacological blocking of
glycolytic enzymes, and induction of glycolytic enzymes by upre-
gulating expression of serine/threonine kinase protein kinase B
(PKB), also known as Akt. Upregulating the expression of Akt
was used as it is known to force induction of glycolytic enzymes
and hence glycolysis in a variety of cell types. Akt activity is also
physiologically relevant to T. gondii biology, as parasite infection
induces host Akt activation and promotes parasite survival by
inhibition of host cell apoptosis (Kim and Denkers, 2006).
As reviewed above, the transcription factor HIF-1a is induced
by hypoxia as well as lactate and functions to upregulate glycol-
ysis. T. gondii infection leads to the upregulation of host HIF-1a
activity, and the induction of HIF-1a-dependent host genes
appears to be required for parasite growth at physiological
oxygen levels. Importantly, induction of host HIF-1a occurs via
a cell-extrinsic mechanism where parasite secretion can induce
HIF-1a activity in uninfected neighboring host cells (Spear et al.,
2006; Weilhammer et al., 2012). Thus it appears that host cell
glycolysis in uninfected cells can inhibit conversion in neighboring
infected cells by the production and release of lactate.
Lactate Shuttles in Resuscitation and Treatment of
Injuries and Illnesses
Given the ongoing revolution in understanding the role of lactate
in metabolism, it is to be expected that some would undertake
using new knowledge to improve outcomes in persons suffering
injuries and illnesses (Brooks and Martin, 2015; Brooks and
Mercier, 1994; Garcia-Alvarez et al., 2014; Marik, 2009). While
elevated blood [lactate] (i.e., hyperlactatemia) is usual in exercise,
particularly high-intensity exercise leading to high blood lactate
levels, high-intensity exercise is increasingly recommended as
a means to reduce risk factors of diabetes, coronary artery
disease (CAD), and cardiometabolic disease (CMD) (Robinson
et al., 2017). Hyperlactatemia is also typical of severe injuries
such as the acute phase of TBI (Glenn et al., 2003), critical ill-
nesses such as sepsis (Shapiro et al., 2005), and organ failure
(Murphy et al., 2001). In clinical settings hyperlactatemia is a
concern because it is a predictor of mortality (Shapiro et al.,
2005; Zhang and Xu, 2014). Typically, the mechanism of lactate-
mia is assumed to be ischemia and hypoxemia. However, as
reviewed by Garcia-Alvarez and colleagues, there is scant
evidence for ischemia, hypoxemia, or tissue hypoxiawhen hyper-
lactatemia occurs in clinical conditions giving rise to hyperlacta-
temia (Garcia-Alvarez et al., 2014; Marik and Bellomo, 2013).
Rather, the association between hyperlactatemia and severity
of injury or illness is traceable to assumptions of O2 debt theory,
now approaching 100 years of age (Hill, 1924; Meyerhof, 1920),
that are contrary to new ideas involving the lactate shuttle mech-
anism (Brooks, 1984, 2009). Therefore, the plea to instructors of
biochemistry and clinicians is to understand lactate shuttling in
mammalian biology as a strain response, the purpose of which
is to mitigate the consequences of illness and injury; lactatemia
is not the cause of injury or illness, but rather amechanism tomiti-
gate the effects of injury and illness. Despite adherence to O2
debt theory by some, clinicians in several specialties in diverse
global locations are investigating and finding successes with
lactate therapy (Bouzat et al., 2014; Nalos et al., 2014; Sharma
et al., 2005, 2008; Wolahan et al., 2017).
Although here we discuss numerous instances in which it may
be clinically beneficial to achieve elevated blood lactate concen-
trations, a comment on the significance of lactate monitoring in
illness when sepsis is suspected or feared is also important to
consider. A blood lactate value of 4 mM is certainly a biomarker
of severe sepsis (Shapiro et al., 2005; Zhang and Xu, 2014). But
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what is the significance of a slightly elevated blood lactate con-
centration of 2.5 mM in a febrile patient when the normal blood
lactate concentration range is 0.8–2.0 mM (Rivers et al., 2001)?
Concern over the prospect of a blooming bacterial, viral, or
fungal attack leading to sepsis needs to be appreciated from
the context of the huge lactate clearance capacity in a healthy
person (Miller et al., 2002b) and also that lactatemia is unlikely
to be due to oxygen insufficiency (hypoxia) (Garcia-Alvarez
et al., 2014; Marik and Bellomo, 2013, 2016). Anecdotally, the
first experiments to use lactate clamp technology to study
glucose-lactate interactions in healthy resting men put us, the in-
vestigators (Miller et al., 2002a, 2002b, 2005), onto a steep
learning curve. From earlier work (Mazzeo et al., 1986; Searle
and Cavalieri, 1972; Stanley et al., 1985) we knew the lactate
production rate in a healthy resting person. So, using a hyperton-
ic L-lactate solution, we gave lactate intravenously at the previ-
ously known Ra, expecting that a doubling of total lactate rate
of appearance (endogenous plus exogenous) would raise blood
[lactate]. But nothing happened to blood [lactate]. Consequently,
we doubled and then tripled the exogenous L-lactate infusion
rate before blood [lactate] rose significantly. So, even though in
previous experiments we had calculated blood lactatemetabolic
clearance rate, we had no appreciation for the huge capacity of a
healthy body to clear lactate. But to the point of recognizing the
importance of a slight or moderate rise in blood [lactate] in
a febrile patient, perhaps with elevated heart and breathing
rates, a warning bell should sound. Specifically, is there some
O2-independent lactate generating infection somewhere that is
either (1) starting to overwhelm the endogenous capacity for
lactate clearance, (2) starting to limit the endogenous capacity
for lactate clearance, or (3) an infection brewing that may give
rise to overwhelming lactate production and/or compromise
lactate clearance capacity? Alternatively, is the body readying
for some challenge by raising the level of a keymyocardial (Berg-
man et al., 2009) and whole-body energy substrate (Brooks,
2002), a gluconeogenic precursor (Bergman et al., 2000; Brooks,
1986; Emhoff et al., 2013b), or an anti-inflammatory moiety
(Hoque et al., 2014; Wu et al., 2011)? Realizing the importance
of lactate in supporting metabolism, some have proposed
Lactated Ringer’s solution as a resuscitation fluid in sepsis
(Marik and Bellomo, 2016), and by extension of the same
thinking, the use of isotonic or hypertonic sodium-L-lactate
and Sanguisal (a contraction from Latin meaning blood [sanguis]
and salt [sal], a physiologically balanced mixture of Na+-, K+-,
Mg2+-, and Ca2+-lactate plus phosphate) also needs to be eval-
uated for resuscitation in sepsis.
Brain Injury
One major area of investigation in which lactate therapy is being
applied experimentally and in clinical trials is the area of resusci-
tation following brain injury. In applying theory to practice, exog-
enous intravenous lactate infusion raising blood lactate concen-
tration to levels of 4–5 mM, as seen in hard exercise (Messonnier
et al., 2013), is being explored in the United States, Europe, and
elsewhere. Despite initial hyperlactatemia as part of the immedi-
ate stress response to injury, in the days following injury inade-
quate nutrition, typically < 50% of need (Finfer et al., 2009),
and glycogen depletion result in low circulating blood lactate
levels after several days of hospitalization following severe TBI
(Glenn et al., 2015a). Low arterial lactate concentration limits
CHO uptake because injury results in a depression in cerebral
glucose uptake (i.e., CMRGlucose) despite administration of
glucose and CHO sources via enteral or parenteral feeding.
Because cerebral lactate uptake is not limited following
brain injury (Glenn et al., 2015b), the strategy of raising cerebral
CHO uptake is to supply intravenous L-lactate, thus bypassing
the injury-imposed limitation in CMRGlucose (Brooks and
Martin, 2015).
Besides providing brain fuel following injury (Glenn et al.,
2015b), L-lactate treatment is anti-inflammatory for two sets of
reasons. First, if the vehicle of L-lactate delivery is intravenous
Na+-lactate, then raising plasma [Na+] may lower intracerebral
pressure (ICP) via an osmotic effect. And second and more
importantly, the L-lactate (not D-) enantiomer (Boysen and
Dorval, 2014; Chan et al., 1994; de-Madaria et al., 2017) is the
effective ligand and binds to the putative lactate receptor
GPR81 (Ahmed et al., 2010; Bergersen, 2015; Lauritzen et al.,
2014) that, via cAMP and CREB, inhibits activation of inflamma-
tory pathways (Hoque et al., 2014).
In terms of route of delivery, providing exogenous L-lactate via
the i.v. mode of administration has advantages, especially when
oral or gastric tube feeding is contraindicated by polytrauma or
other complications. Depending on an individual’s nutritive and
physiological state, compared to that for glucose, lactate turn-
over can vary widely (Bergman et al., 1999a, 1999b; Messonnier
et al., 2013; Stanley et al., 1988). Hence, rather than provide a
L-lactate dose related to bodymass, age, and gender, investiga-
tors set the lactate infusion dose to that which achieves a tar-
geted (clamped) blood lactate concentration. In one study the
L-lactate clamp (LC) was 2 mM (Wolahan et al., 2017). However,
because the mass of lactate is essentially half that of glucose,
other investigators have set LC targets to 4–5 mM (Bouzat
et al., 2014; Patet et al., 2016; Quintard et al., 2016; Wolahan
et al., 2017). Brain injury conditions to which LC treatments
have been applied include TBI (Patet et al., 2016; Quintard
et al., 2016; Wolahan et al., 2017) and subarachnoid hemorrhage
(Oddo et al., 2012).
Heart Failure
During rest or exercise, lactate is a major fuel for the healthy
heart; in fact, as a cardiac fuel, L-lactate is preferred over
glucose and free fatty acids (Bergman et al., 2009; Gertz et al.,
1981, 1988). Accordingly, it is not surprising that the treatment
of heart failure is moving in the direction of providing exogenous
lactate to improve cardiac function (Nalos et al., 2014; Sharma
et al., 2008, 2005) (Figure 5).
Chronic, Obstructive Pulmonary Disease (COPD) and
Heart Disease
Acute high altitude exposure results in lactatemia in resting
individuals and greater blood lactate accumulation during given
exercise power outputs compared with sea level (vide supra).
Lactatemia at high altitude (i.e., the ‘‘lactate paradox’’) has
been found to be due to activation of the sympathetic nervous
system and not oxygen lack (vide supra) (Brooks et al., 1991a,
1991b). Lactatemia and hyperlactemia on easy exertion at sea
level is characteristic of those with asthma and other forms of
pulmonary disease (Casaburi et al., 1991) as well as heart dis-
ease and other conditions that limit pulmonary oxygen diffusion
and systemic oxygen transport (Wasserman and McIlroy, 1964).
Blood lactate and resulting ventilatory responses to graded
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exercise (i.e., determining lactate and ventilatory ‘‘thresholds’’)
are widely used paradigms in pulmonary and sports medicine,
but interpretation of data is limited by the failure of clinicians
to monitor parameters of lactate kinetics and responses of
the sympathetic nervous system in response to hypoxemia
(San-Milla´n and Brooks, 2018). Results exist only for graded
(Messonnier et al., 2013) and continuous leg cycling exercise
tests (Bergman et al., 1999b), and those results clearly indicate
that the lactate threshold is attributable to an imbalance between
the appearance of lactate in and disposal from blood. However,
the meaning of blood lactate and ventilatory thresholds in activ-
ities such as running and swimming has not been studied and
consequently is unknown.
Inflammation
Intravenous L-lactate infusion has the capability of minimizing
cerebral swelling and ICP following brain injury, but vascular
L-lactate infusion has the potential to minimize inflammation in
other injured tissues aswell. Notably, L-lactate therapy is attract-
ing attention and consideration for use in a variety of other ther-
apies, including pancreatitis (Hoque et al., 2014; Wu et al., 2011),
hepatitis (Hoque et al., 2014), dengue fever (Somasetia et al.,
2014), and sepsis (Marik and Bellomo, 2016).
When Lactate Shuttling May Be Maladaptive
Until now in this review, normal physiological functioning of
lactate shuttles has been emphasized; however, there are cases
in which lactate shuttling can be problematic or pathological. For
instance, in cancer, aggressiveness of the disease is associated
with the extent of hyperlactatemia (Hanahan and Weinberg,
2011). There is a long history of interest in lactate production
and accumulation in cancer research (the ‘‘Warburg effect’’),
and recently investigators have sought to block lactate shuttling
in tumors by blocking MCTs (Sonveaux et al., 2008). Recently
also, in the field of diabetes, research investigators have sought
to understand why MCT expression is silenced in pancreatic b
cells such that they do not participate in lactate shuttling
(Ishihara et al., 1999; Otonkoski et al., 2007). Silencing of
MCT1 expression and insertion into the plasma membrane is
necessary to prevent hypersecretion of insulin and profound
hypoglycemia when blood lactate is high and blood glucose is
low, as occurs in physical exercise.
Lactate Shuttles in Cancer Metabolism
In 1923 Otto Warburg observed the first phenotypic characteris-
tics of cancer cells; they demonstrated increased glucose up-
take and excessive lactate formation even under fully oxygen-
ated conditions (Warburg and Minami, 1923). Warburg’s
discovery was subsequently named the ‘‘Warburg effect’’
(Racker, 1972). The high glucose uptake/lactate release pheno-
type remains a hallmark of cancer (Hanahan and Weinberg,
2000; Koppenol et al., 2011), but today there is no consensus
on the meaning of the observations. It was the excessive lactate
formation that struck Warburg and led him to propose that can-
cer was an injury to the cellular respiratory apparatus. In a recent
review, San-Milla´n and I (San-Milla´n and Brooks, 2017)
described many similarities between cancer and healthy exer-
cise phenotypes. Consequently, we proposed that augmented
lactate production (‘‘lactagenesis’’) initiated by gene mutations
is the reason and purpose of the Warburg effect and that dysre-
gulated lactate metabolism and signaling are key elements in
carcinogenesis (San-Milla´n and Brooks, 2017). In this regard it
is to be noted that we are not the only physiologists to have com-
mented on the meaning of the Warburg effect in an age when
there is growing understanding of lactate shuttling (Goodwin
et al., 2015). An abbreviated justification of our hypothesis
(San-Milla´n and Brooks, 2017) is given below.
Lactate Production in Carcinogenesis
In lactagenic cancers, oncogenes andmutated tumor suppressor
factors behave with the apparent purpose of reprogramming
glycolysis for lactagenesis, thus creating concentration gradients
for lactate exchange within, between, and among cells. We (San-
Milla´n and Brooks, 2017) identified the following steps by which
lactagenesis may support carcinogenesis: (1) increased glucose
uptake; (2) increased glycolytic enzyme expression and activity;
(3) decreased mitochondrial function; (4) increased lactate
production, accumulation, and release; and (5) upregulation of
monocarboxylate transporters MCT1 and MCT4 for lactate ex-
change. Not only is lactate present as the result of aberrant, inef-
ficient metabolism, but because of its autocrine-, paracrine-, and
endocrine-like characteristics we postulate that lactate partici-
pates in driving main sequela for carcinogenesis, specifically
angiogenesis, immune escape, cell migration, metastasis, and
self-sufficient metabolism. Accordingly, developing therapies
that limit lactate exchange and signaling within and among can-
cer cells should be priorities for cancer research (San-Milla´n
and Brooks, 2017).
Lactate Promotes Angiogenesis
It is well known that lactate is a key player in angiogenesis
because it (lactate) stimulates release of vascular endothelial
growth factor (VEGF) for wound healing and repair (Hunt et al.,
2008; Kumar et al., 2007; Trabold et al., 2003). In cancer, lactate
stimulates VEGF protein expression in endothelial cells (Dhup
et al., 2012; Polet and Feron, 2013; Ve´gran et al., 2011) in a con-
centration-dependent manner (Beckert et al., 2006). When
lactate production is blocked using oxamate, a LDHA inhibitor,
angiogenesis is greatly reduced (Hunt et al., 2008). Related is
that LDH knockout inhibits cancer cell proliferation (Fantin
et al., 2006; Shim et al., 1997), while approaches to target
MCTs, thereby blocking lactate transport across cancer cell
membranes, have shown effectiveness in decreasing both
angiogenesis and cell migration (Doherty et al., 2014; Draoui
and Feron, 2011; Sonveaux et al., 2012).
Lactate Influences Acidity of the Tumor
Microenvironment (TME)
The TME is an active niche that shapes tumor pathogenesis and
evolution (Chen et al., 2015). The TME consists of malignant
cells, immune cells, non-cancer cell stromas, fibroblasts, and
the vasculature and lymphatics. Because MCTs are symporters,
cotransporting lactate anions and protons, the intracellular pH
(pHi) in cancer cells tends to be slightly alkaline compared to
the extracellular space into which protons are excreted (Gillies
et al., 2002; Stubbs et al., 2000). In normal cells, pHi approxi-
mates 7.2. However, in cancer cells pHi approximates 7.4
(Webb et al., 2011), or the pH of normal arterial blood. In contrast,
an extracellular pH of 5.5–7.0 is common in cancers (Justus
et al., 2013; Webb et al., 2011). As the result of constant lactate
and hydrogen ion extrusion from cancer cells by ontogenetic-
derived MCT overexpression, the TME becomes an acidic envi-
ronment, which seems to be key for carcinogenesis (Gillies et al.,
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2002; Stubbs et al., 2000). In fact, TMEs with the lowest pH
correlate with the highest level of invasion and vice versa (Corbet
and Feron, 2017).
Lactate Promotes Cell Migration, Metastasis, and
Exosome Release
Cell migration is an essential step in carcinogenesis and metas-
tasis. Among other factors, lactate appears to be necessary for
endothelial cell migration (Beckert et al., 2006; Walenta and
Mueller-Klieser, 2004) in a concentration-related manner (Goetze
et al., 2011). Further, in glioma cells, lactate induces the expres-
sion of transforming growth factor-b2 (TGF-b2), a key regulator of
glioma cell migration (Baumann et al., 2009). A role for lactate in
stimulating metastasis has long been suspected because of the
correlation between lactate level and the extent of metastasis in
different forms of cancers (Brizel et al., 2001; Dhup et al., 2012;
Schwickert et al., 1995; Walenta and Mueller-Klieser, 2004).
Exosomes are considered by some to represent another
mechanism for tumor metastasis. Exosomes are microvesicles,
30–100 nm in size, of endocytic origin that contain microRNAs,
proteins, metabolic enzymes, and structural proteins represen-
tative of the cells from which they originate. Secreted cancer-
derived exosomes can be transferred to stroma cells in the
cancer microenvironment and may induce epigenetic changes
and elicit cancer phenotype in target cells by transferring genetic
information including oncogenes and onco-miRNAs (Kharaziha
et al., 2012). Cancer-associated fibroblast exosomes provoke
metabolic reprograming in other cancer cells by inhibiting mito-
chondrial function and upregulating glucose metabolism (Zhao
et al., 2016). In cancer patients tumor-derived exosome release
correlates with poor prognosis (Kim et al., 2003). An important
regulator of exosome release by tumors is low pH in the tumor
microenvironment, caused by the release of protons and lactate
anions fromwithin rapidly glycolyzing cancer cells (Parolini et al.,
2009). Treatment with proton pump inhibitors results in a marked
inhibition of exosome release by tumor cells (Federici et al., 2014)
and inhibition of exosome trafficking in tumors (Parolini et al.,
2009). Because low pH can also be crucial in exosome release
and uptake, blockingMCT expression or action in the TMEmight
be a viable way of limiting lactate shuttling within a tumor.
Lactate Plays a Role in ‘‘Immune Escape’’
Lactate appears to contribute to the immune escape by effects
on monocytes, T cells, and natural killer (NK) cells. Monocytes
are highly motile cells and precursors of tumor-associated mac-
rophages. Lactate inhibits monocyte migration and the release
of cytokines TNF and IL-6 (Goetze et al., 2011). As well, lactate
appears to have a bimodal effect on T cell activation. On one
hand, T cell activation increases glycolysis and lactate accumu-
lation due to low cellular mitochondrial content (Michalek and
Rathmell, 2010), but on the other hand, lactate accumulation in
the TME opposes T cell lactate efflux, leading to decreased
cytokine production and cytotoxic activity of human T cells
(Fischer et al., 2007). This conclusion about the effect of lactate
accumulation on T cells in the TME (San-Milla´n and Brooks,
2017) is supported by a recent report that tumor-derived lactate
accumulation translationally inhibits expression of adhesion
kinase family-interacting protein of 200 kD (FIP200) by
downregulating NAD+ cytosol level while upregulating the inhib-
itory effect of adenylate-uridylate-rich elements within the 30
untranslated region of Fip200 mRNA (Xia et al., 2017). Further,
lactate inhibits the differentiation of monocytes to dendritic cells
(Gottfried et al., 2006; Puig-Kro¨ger et al., 2003). And finally,
lactate in the TME inhibits NK cell function directly by inhibiting
cytolytic function and indirectly by increasing the numbers of
myeloid-derived suppressor cells that inhibit NK cytotoxicity
(Husain et al., 2013). Hence, via lactate production and accumu-
lation, the Warburg effect may contribute to immune escape in
carcinogenesis.
Lactate Is Necessary for Cancer Cell Self-Sufficiency
and Sustained Glycolysis
Both directly, as an energy source, and indirectly, as a gluconeo-
genic precursor, lactate plays a central role in the bioenergetics
and self-sufficiency of cancer cells. Chronic sustained high rates
of glycolysis in cancer cells will eventually deplete their own and
then the body’s glucose and glycogen reserves necessary to
sustain high rates of glucose uptake in cancer cells. Subse-
quently, with glucose and glycogen depletion in the host patient,
counter-regulatory mechanisms to maintain euglycemia will
result in catabolism of body tissue protein reserves.
Carbon recycling in the Cori cycle arm of lactate shuttling is
typically portrayed as a means to preserve euglycemia in a per-
son, but effectiveness of the cycle is short-term and imperfect
because both the precursor and products of glycolysis (glucose
and lactate, respectively) are oxidized and thus depleted during
functioning of the cycle. Consequently, as in other instances
such as prolonged exercise and lack of CHO nutrition, body
corpus amino acid and protein reserves are called upon to
ensure long-term maintenance of euglycemia in the host.
Cachexia in cancer stresses the total body nitrogen pool as
well as reserves of particular amino acids, particularly glutamine,
as glutaminolysis is upregulated in many types of cancers (Daye
and Wellen, 2012; Medina, 2001). Glutamine is converted to
glutamate by glutaminase (GLS) that is overexpressed in can-
cers and regulated by c-MYC (Wise et al., 2008). Subsequent
to conversion to glutamate, the carbon skeleton originating
from glutamine is a readily available oxidative substrate via entry
into the mitochondrial TCA cycle.
Beyond serving as an energy substrate via conversion to
glutamate, in cancer, glutaminolysis also produces lactate. The
pathway involves oxidation of glutamine to malate and then to
pyruvate by malic enzyme (ME), which is overexpressed in
different cancers and regulated by p53 (Jiang et al., 2013).
Following conversion to pyruvate by the action of LDHA, which
is overexpressed in lactagenic cancers (Brand et al., 2016;
Shim et al., 1997), glutaminolysis leads to an increase in lactate
production (San-Milla´n and Brooks, 2017). Further, in oxidative
cancer cells, lactate promotes glutamate uptake and catabolism
by increasing the expression of glutamine transporter ASCT2
and of glutaminase 1 (GLS1) (Pe´rez-Escuredo et al., 2016).
Thus, in cancer, glutaminolysis can be regarded as a secondary
carbon source for lactagenesis; by direct and indirect mecha-
nisms, glutaminolysis both fuels cancer cells and depletes the
host’s body of CHO, amino acids, and protein reserves.
Lactate as a Transcription Factor
Exercise, including vigorous exercise leading to lactatemia, re-
duces cancer risk (Gohil and Brooks, 2012; Lee et al., 2012;
Ruiz-Casado et al., 2017), but because of classic findings around
the Warburg effect involving augmented glucose uptake and
lactate production, concern persists over whether high-intensity
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exercise involving increased glucose and lactate flux rates might
provoke carcinogenesis or recurrence of cancer (Toohey et al.,
2016). Rephrased, there is concern that lactatemia from high-
intensity exercise could be a gene regulator contributing to
metabolic reprogramming and development of the ‘‘cancer
phenotype.’’ We have shown that exposure to 10–20 mM of
lactate upregulated 673 genes in non-transformed L6 cells
(Hashimoto et al., 2007). Further, with MCF7 cells incubated in
10 mM lactate, a concentration observed in many cancer cells,
"4,131 genes were upregulated (Martinez-Outschoorn et al.,
2011). Lactate increases MCT1 expression that is enhanced by
c-Myc and p53. Further, the master transcription factor involved
in tumor cell glycolysis, HIF-1, has been shown to be activated
by lactate in different cancer lines (De Saedeleer et al., 2012;
Lu et al., 2002; Semenza, 2010). Hence, it is plausible to think
that the thousands of genes upregulated by lactate may collec-
tively represent a transcriptional network involved in reprogram-
ming cells for lactagenesis and perhaps carcinogenesis.
Blocking Lactate Shuttles in Cancer
Since Sonveaux et al. in the Feron lab identified lactate shuttling
in tumors (Sonveaux et al., 2008), there have been serious
attempts to repress tumorigenesis by blocking the release of
lactate from glucose-consuming and highly glycolytic cells and
cells respiring lactate. That cancer cells respire with lactate drawn
from the TME is an important realization in itself (Hensley et al.,
2016; Hussien and Brooks, 2011), but also oxidative lactate
disposal within tumors sets up the concentration gradient neces-
sary for lactate shuttling. Following the lead of Sonveaux et al.
(Sonveaux et al., 2008), the search is on to develop MCT1 and
MCT4 inhibitors (Doherty and Cleveland, 2013; Doherty et al.,
2014; Draoui and Feron, 2011; Draoui et al., 2014; Sonveaux
et al., 2008). However, lack of MCT specificity has been a prob-
lem. Recently, AstraZeneca developed a specific MCT1 and
MCT2 inhibitor, AR-C155858 (Ovens et al., 2010), inhibiting
MCT1 and MCT2 expression in Ras-transformed fibroblasts.
However, the cells developed resistance to the inhibition of
MCT1 and MCT2 and increased carcinogenesis by overexpress-
ingMCT4 (Le Floch et al., 2011). Newgenerations ofMCT-1 inhib-
itors have shown promising results in Raji cells (Doherty et al.,
2014) and small-cell lung cancer (Pola"nski et al., 2014). However,
the quest to find cancer-specific MCT blockers has as yet
been unsuccessful; hence, others are looking for alternative ap-
proaches to blocking lactate shuttling in tumors and cancer,
such as by limiting expression of CD147, the scaffold for MCT
insertion into cell membranes (Baba et al., 2008; Schneiderhan
et al., 2009; Su et al., 2009; Zou et al., 2007).
Lack of MCT Pancreatic b-Cell MCT Silencing Can
Interfere in the Regulation of Glycemia
Lactate-glucose interactions can be complex, and by interfering
with glucose-insulin signaling, lactate shuttling can be disrup-
tive. Glucose and glycogen are the precursors to lactate
formation (Brooks, 2002; Hultman, 1967), and lactate is themajor
gluconeogenic precursor (Bergman et al., 2000; Cori and Cori,
1946; Emhoff et al., 2013b; Meyer et al., 2002a, 2002b). How-
ever, whereas blood glucose level plays an important role in
the regulation of its clearance rate via influencing the levels of
insulin and counter-regulatory hormones, other than providing
precursor material for gluconeogenesis, lactate is excluded
from processes related to insulin secretion.
MCTs are ubiquitous, expressed in most tissues (Brooks,
2009; Garcia et al., 1994; Price et al., 1998), where they support
lactate shuttling. The importance of lactate in metabolic regula-
tion is further emphasized by exclusion of MCTs from insertion
into pancreatic b cell plasma membranes (Pullen et al., 2010;
Rutter et al., 2015). There, MCT expression is silenced to keep
extracellular lactate from affecting intracellular redox and inter-
fering with glucose sensing and insulin secretion (Bender et al.,
2006). The silencing of MCT1 in pancreatic b cells is evolutionary
proof of how lactate overrides glucose in regulating energy sub-
strate partitioning in general and insulin secretion in particular
when the dominant role of lactate must be suppressed. Note-
worthy in this regard is that individuals experiencing failed
suppression of pancreatic b cell MCT expression become hypo-
glycemic during hard exercise, leading to lactatemia as lactate
gains entry to pancreatic b cells and affects cell redox as if blood
glucose was elevated. In these individuals, unlike in healthy con-
trols, aberrant entry of lactate into pancreatic b cells causes
insulin secretion during exercise. The combination of high insulin
and increased glucose disposal through metabolism causes
hypoglycemia (Otonkoski et al., 2007).
What Can Be Learned by Distinguishing between the
Terms ‘‘Aerobic Glycolysis’’ and ‘‘Fermentation’’ in
Understanding Lactate Metabolism?
As assessed from recent literature, more and more diverse sets
of investigators are finding support for the lactate shuttle hypoth-
esis. In some aspects, confirmation of the hypothesis is helpful in
terms of science. As well, confirmation is necessary because of
the intellectual and organizational silos we live and work in;
hence the lactate shuttle, a theory of metabolic organization
developed in exercise physiology and metabolism, needed to
be tested by investigators in neuroscience and cancer research
who will accept results of their own investigations. For instance,
using isotope tracer technology onmice, investigators (Hui et al.,
2017) recently stated that ‘‘intravenous infusions of 13C-labeled
nutrients reveal that, on a molar basis, the circulatory turnover
flux of lactate is the highest of all metabolites and exceeds that
of glucose by 1.1-fold in fed mice, and 2.5-fold in fasting
mice.’’ The same authors concluded that ‘‘analysis reveals that
during the fasted state, the contribution of glucose to tissue
TCA metabolism is primarily indirect (via circulating lactate) in
all tissues except the brain.’’ However, all of this had been shown
previously on mammalian models (Depocas et al., 1969; Fremi-
net et al., 1974) and humans (Bergman et al., 2009; Brooks
et al., 1991a; Messonnier et al., 2013; Miller et al., 2002a,
2002b; Stanley et al., 1988). Further, the statement about brain
lactate metabolism by Hui et al. (Hui et al., 2017) is imprecise
because it has been shown that lactate is preferred over glucose
when arterial [lactate] is raised by physical exercise (Hashimoto
et al., 2018; van Hall et al., 2009) or exogenous infusion (Brooks
and Martin, 2015; Glenn et al., 2015b; Wolahan et al., 2017)
(Figure 5).
With regard to recent replication of previous results, other
investigators (Chen et al., 2016) used solid-state NMR, high-
resolution mass spectrometry (HRMS), and transmission
electron microscopy (TEM) on isolated cells in vitro to confirm
important aspects of lactate shuttling and mitochondrial lactate
oxidation. 13C-NMR spectral analysis showed mitochondrial
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lactate oxidation in cultured HeLa cells in vitro; the results help
generalize previous results obtained by MRS on rat muscle in
the Tom Jue lab (Park et al., 2015); on lactate oxidation in mito-
chondria isolated from rat muscle, heart, and liver (Brooks et al.,
1999a; Kline et al., 1986); and on human skeletal muscle (Jacobs
et al., 2013). Also, the authors (Chen et al., 2016) did well using
TEM to show the presence of LDH in mitochondria of HeLa cells,
but again, the presence of mitochondrial LDH has previously
been shown in mammalian (Baba and Sharma, 1971; Brooks
et al., 1999c) including human tissues (Dubouchaud et al.,
2000) using EM. As well, mitochondrial LDH has been previously
demonstrated by other methods, such as differential centrifuga-
tion followed by immunocoprecipitation and immunocytochem-
istry, onmuscle-derived cell lines and rat (Hashimoto et al., 2006,
2005) and human muscles (Dubouchaud et al., 2000) as well as
rat brain in vivo (Hashimoto et al., 2008).
In science, replication is important, but even so, from my
perspective it is genuinely puzzling why so many contemporary
investigators struggle to comprehend lactate shuttle theory.
Perhaps comprehension is low due to reliance on outdated and
inappropriate textbook terminology. Consider, for instance, inter-
pretation of data by authors who studied a variety of cell types
and intact mice under fully aerobic conditions (Chen et al.,
2016; Hui et al., 2017). The investigators could not escape from
thinking of and presenting their ideas in terms of ‘‘fermentation.’’
An example of how loose usage of terminology leads to misun-
derstanding is illustrated by this (incorrect) Wikipedia entry:
‘‘Fermentation is a metabolic process that consumes sugar in
the absence of oxygen. The products are organic acids, gases,
or alcohol. It [fermentation] occurs in yeast and bacteria and
also in oxygen-starved muscle cells, as in the case of lactic
acid fermentation’’ (https://en.wikipedia.org/wiki/Fermentation).
In human physiology, use of the term ‘‘fermentation’’ is appro-
priatewhen describingmetabolism of gutmicrobiota (vide supra).
Andwhile bacteria in themicrobiome are on us and in our gut, use
of such terminology for understanding mammalian or human
intermediary metabolism is unfortunate because the Wiki defini-
tion is not correct for intermediary metabolism in cells, organs,
and tissues of mammals and humans. Further, the Wiki definition
is lacking for understanding of human intermediary metabolism
because there is no distinction between the metabolism of L-
and D-lactate enantiomers. Hence, the concept of fermentation
in guiding mammalian metabolism needs to be discarded
because it ignores the fact that lactate production occurs contin-
uously under fully aerobic conditions in humans and other mam-
mals in vivo. And, of course, alcohol production is not a feature of
glycolysis in human or mammalian metabolism.
The importance of proper terminology in describing glycolysis
in mammalian and human systems has long been a feature of
discussion in human physiology (Brooks and Fahey, 1984;
Connett et al., 1990). However, with the advent of interest in
the microbiome, physiologists, biochemists, and nutritionists
focusing on the human condition need to become aware that
fermentation takes place in the gut and the products include
D- as well as L-lactate (vide supra).
Synopsis
Studies onmammals, including humans, during rest and exercise
led to discovery of the lactate shuttle, a mechanism by which
lactate production in rapidly glycolyzing cells provides energy
substrate for recipient cells where lactate is a fuel energy source,
gluconeogenic precursor, and signaling molecule. In heart and
red skeletal muscle, lactate disposal is by mitochondrial respira-
tion. In the liver and kidneys, mitochondria play roles in oxidizing
lactate to pyruvate and then in the conversion to oxaloacetate
and phosphoenolpyruvate via pyruvate carboxylase and phos-
phoenolpyruvate carboxykinase. As well, in the liver and kidneys,
the oxidation of lactate and other fuel sources provides energy
for completion of gluconeogenesis and glycogen synthesis. By
changes in cell redox owing to the production and oxidation of
lactate, as well as allosteric binding to GPR81, lactate affects
numerous processes. Discoveries of many intracellular, cell-
cell, and organ-organ lactate exchanges has led to articulation
of numerous ‘‘lactate shuttles,’’ the basis of which are interactive
effects between producer and consumer cells.
It is anticipated that when clinicians better understand that
glycolysis leading to lactate production is part of normal, aerobic
physiology, they will be better able to treat the ill and injured. For
example, exogenous L-lactate vascular infusion is being evalu-
ated in the treatment of heart failure (Nalos et al., 2014; Sharma
et al., 2008, 2005), TBI (Brooks and Martin, 2015; Oddo et al.,
2012; Patet et al., 2016; Wolahan et al., 2017), pancreatitis
(Hoque et al., 2014; Wu et al., 2011), hepatitis (Hoque et al.,
2014), dengue fever (Somasetia et al., 2014), and sepsis (Marik
and Bellomo, 2016).
Recognizing also that rising lactate level is a biomarker for an
imbalance in lactate Ra and Rd, in diverse fields clinicians are
paying increasing attention to the meaning of a rise in blood
[lactate]. Those fields range from exercise physiology and sports
medicine (Hofmann and Pokan, 2010; San-Milla´n and Brooks,
2018) to critical care medicine (Marik and Bellomo, 2013) and
oncology (Sonveaux et al., 2008). Indeed, recognition that
lactate shuttles among producer (driver) and consumer (recip-
ient) cells in tumors offers the exciting possibility of reducing
carcinogenesis and tumor size by blocking producer and recip-
ient arms of lactate shuttles within and among tumor cells. As
well, with appreciation of the importance and extent of lactate
shuttling in vivo, it is to be anticipated that by controlling blood
[lactate] via a closed-loop continuous monitoring system
involving infusion of more or less lactate-containing, gluconeo-
genic, or monocarboxylate-containing solutions, the standard
of care for treatment of the ill, injured, and malnourished will be
improved (Horning and Brooks, 2012a, 2012b, 2015).
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